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Preeclampsia is a disease of the mother, fetus, and placenta, and the gaps in our under-
standing of the complex interactions among their respective disease pathways preclude 
successful treatment and prevention. The placenta has a key role in the pathogenesis 
of the terminal pathway characterized by exaggerated maternal systemic inflammation, 
generalized endothelial damage, hypertension, and proteinuria. This sine qua non of pre-
eclampsia may be triggered by distinct underlying mechanisms that occur at early stages 
of pregnancy and induce different phenotypes. To gain insights into these molecular 
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pathways, we employed a systems biology approach and integrated different “omics,” 
clinical, placental, and functional data from patients with distinct phenotypes of pre-
eclampsia. First trimester maternal blood proteomics uncovered an altered abundance 
of proteins of the renin-angiotensin and immune systems, complement, and coagulation 
cascades in patients with term or preterm preeclampsia. Moreover, first trimester mater-
nal blood from preterm preeclamptic patients in vitro dysregulated trophoblastic gene 
expression. Placental transcriptomics of women with preterm preeclampsia identified 
distinct gene modules associated with maternal or fetal disease. Placental “virtual” liquid 
biopsy showed that the dysregulation of these disease gene modules originates during 
the first trimester. In vitro experiments on hub transcription factors of these gene mod-
ules demonstrated that DNA hypermethylation in the regulatory region of ZNF554 leads 
to gene down-regulation and impaired trophoblast invasion, while BCL6 and ARNT2 
up-regulation sensitizes the trophoblast to ischemia, hallmarks of preterm preeclampsia. 
In summary, our data suggest that there are distinct maternal and placental disease 
pathways, and their interaction influences the clinical presentation of preeclampsia. The 
activation of maternal disease pathways can be detected in all phenotypes of preeclamp-
sia earlier and upstream of placental dysfunction, not only downstream as described 
before, and distinct placental disease pathways are superimposed on these maternal 
pathways. This is a paradigm shift, which, in agreement with epidemiological studies, 
warrants for the central pathologic role of preexisting maternal diseases or perturbed 
maternal–fetal–placental immune interactions in preeclampsia. The description of these 
novel pathways in the “molecular phase” of preeclampsia and the identification of their 
hub molecules may enable timely molecular characterization of patients with distinct 
preeclampsia phenotypes.
Keywords: inflammation, ischemia, liquid biopsy, omics, placenta, pregnancy, systems biology, trophoblast invasion
inTrODUcTiOn
Preeclampsia, one of the most severe obstetrical complications 
affecting 5–8% of pregnant women (1–5), is a leading cause 
of maternal (4–15) and perinatal morbidity and mortality (6, 
16–18). In addition, pathologic changes in the affected mothers 
and fetuses lead to a higher risk of subsequent metabolic and 
cardiovascular diseases later in life (8, 9, 11, 13, 19–23), further 
increasing healthcare costs. In spite of the severity of the problem, 
there is yet no early diagnosis of all forms of preeclampsia, and 
the current therapy is still based on the delivery of the placenta 
(2, 24), given the complexity of the disease and the lack of insight 
into the early perturbed molecular pathways.
Indeed, preeclampsia is a syndrome with heterogeneous etiol-
ogy and a spectrum of phenotypes (Figure 1). It may affect women 
at varying gestational ages with different degrees of severity and 
consequences for the fetus (2, 25–31). The current classifications 
of preeclampsia are based upon its severity and the timing of 
clinical presentation, mostly dividing preeclampsia into preterm 
(<37 weeks) or term (≥37 weeks) and early-onset (<34 weeks) 
or late-onset (≥34 weeks) phenotypes (24, 26, 32–36). Preterm 
preeclampsia has a more severe clinical presentation and is often 
accompanied by fetal growth restriction compared to term preec-
lampsia (2, 25, 26, 29). However, severe maternal disease and fetal 
growth restriction may be observed in both term and preterm 
preeclampsia, and their presentation may not be associated with 
each other, suggesting that the clinical phenotype is the result of 
an interplay between various factors and disease pathways, also 
supported by observations in animal models (37).
A growing body of evidence offers support for the conclusion 
that the maldevelopment and/or dysfunction of distinct trophoblast 
lineages of the placenta have a central role in the pathogenesis of 
preeclampsia, and that the severity of the placental disease is sub-
sequently reflected in the clinical phenotype of this syndrome. In 
the preclinical stage, extravillous trophoblast (EVT) development 
may be impaired, leading to EVT dysfunction, shallow trophoblast 
invasion, failure of the physiological transformation of the maternal 
spiral arteries, abnormal blood-flow to the placenta, and histologi-
cal changes consistent with maternal vascular malperfusion (28, 
30, 38–43). The frequency and severity of these lesions decrease 
from the preterm toward the term phenotype of preeclampsia (28, 
33, 44–46) (Figure 1), mirrored by the decreasing prevalence of 
fetal growth restriction or the delivery of small-for-gestational age 
(SGA) neonates (47–53). Thus, EVT development is less frequently 
and extensively affected in late-onset preeclampsia, which consti-
tutes about 90% of all cases (50, 54, 55).
In preterm preeclampsia, failure of the remodeling of the 
spiral arteries may lead to abnormal blood flow to the placenta 
and subsequently to placental structural damage and ischemic 
stress, villous trophoblast (VT) dysfunction and the release of 
FigUre 1 | Pathogenesis of preeclampsia. Preeclampsia is a syndrome with 
heterogeneous etiology and a spectrum of phenotypes. It may appear at 
varying gestational ages with different degrees of severity and involvement of 
the fetus. Preterm, especially early-onset preeclampsia generally has a more 
severe clinical presentation in the mother and is more often associated with 
the delivery of a growth-restricted neonate than term or late-onset 
preeclampsia. It is a multi-stage disease with the maldevelopment and/or 
dysfunction of distinct trophoblast lineages of the placenta at the center of 
the disease. Villous and extravillous trophoblast (EVT) development and/or 
function may be impaired in the preclinical stage, most extensively in preterm 
preeclampsia associated with fetal growth restriction. The resulting abnormal 
maternal spiral artery remodeling, fluctuating blood-flow, and ischemic stress 
lead to placental histological changes and the release of harmful substances 
from the placenta. As a consequence, the terminal pathway of preeclampsia, 
an exaggerated maternal systemic inflammatory and anti-angiogenic 
condition, occurs. The frequency and severity of placental developmental 
problems continuously decrease with advancing gestational age. In term 
forms, other stressors than maternal vascular malperfusion and placental 
ischemia may trigger placental stress, trophoblastic dysfunction, and the 
induction of the terminal pathway. Alternatively, the maternal endothelium 
may have an exaggerated sensitivity to factors released from a relatively 
normal placenta.
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detrimental placental substances (e.g. anti-angiogenic factors, 
pro-inflammatory cytokines, and syncytiotrophoblast debris) 
into the maternal circulation (40, 41, 43, 56–66). As a conse-
quence, the terminal pathway of preeclampsia, featuring an 
anti-angiogenic state and exaggerated maternal systemic inflam-
mation, occurs in most cases, and its intensity correlates with the 
severity of preeclampsia, which may be coupled with damage to 
the maternal endothelium and to the kidneys, liver, and central 
nervous system during the clinical phase (21, 42, 43, 64, 67–72). 
VT development can also be impaired in preeclampsia (73–75), 
especially in the preterm form associated with SGA, where VT 
turnover is affected together with morphometric features (73, 76).
Term preeclampsia is characterized by a lesser magnitude 
of maternal systemic inflammatory and anti-angiogenic states 
(30, 37, 55–57, 61, 62, 77–92). This phenotype may result from 
different stressors other than maternal vascular malperfusion 
and ischemia of the placenta, which include various preexisting 
maternal disorders, such as obesity, chronic hypertension, diabe-
tes, and metabolic, kidney, and autoimmune diseases (25, 93, 94). 
These stressors may still trigger placental stress and VT 
dysfunction (31, 91) and induce a maternal pro-inflammatory 
milieu. Alternatively, maternal endothelial dysfunction may 
result from an exaggerated sensitivity to factors released from the 
placenta (21, 25, 31, 95), which increases the risk of preeclampsia 
upon maternal genetic predisposition for cardiovascular disease 
(96, 97). Indeed, preeclampsia has a genetic predisposition with 
high heritability of both phenotypes, and it shares common risk 
alleles with coronary artery disease (98–104).
In spite of extensive research efforts, our understanding of the 
early pathologic pathways of preeclampsia has been limited given 
several obstacles. First, the complexity of the disease pathways 
and the heterogeneity of the syndrome have not been investigated 
in an integrative manner in both maternal and placental com-
partments throughout pregnancy. Second, it has been impossible 
to investigate the early placental disease pathways because of the 
invasive nature of placental biopsy and the limited information 
on placental functions obtained non-invasively. Consequently, an 
increasing number of high-dimensional studies aiming to detect 
molecular signatures of preeclampsia either in the placenta or in 
maternal blood have mostly targeted later stages of pregnancy, at 
a more advanced stage of placental development and pathology 
(105–143). Third, animal models of preeclampsia fail to mimic 
early placental pathways of preeclampsia due to the anatomical 
and physiological uniqueness of deep placentation in humans 
(144–147). Fourth, in vitro studies on human placental develop-
ment and trophoblast functions are hindered by the lack of self-
replicating trophoblast stem cells with the ability to differentiate 
into both VTs and EVTs (148–150).
Here, we used a systems biology approach that integrated 
various omics and targeted methods to investigate both placental 
and maternal compartments and most aspects of preeclampsia, 
including placental disease; fetal and maternal outcomes; envi-
ronmental, maternal, microenvironmental, and epigenetic fac-
tors; and trophoblastic functions. In the first placental study, we 
performed extensive investigations of the placenta at histologic, 
transcriptomic, epigenetic, and protein levels to target molecular 
pathways at the center of the disease. Molecular changes were 
correlated with maternal and neonatal morbidities associated 
with preeclampsia to uncover placental pathways affecting either 
maternal or fetal wellbeing. In the second, maternal study, we 
employed maternal blood proteomics and “virtual” liquid biopsy 
of the placenta to reveal blood factors of maternal or placental 
origin that can reflect disease conditions in early pregnancy. In 
the third, trophoblast study, we utilized in vitro functional assays 
on the trophoblast to investigate hub transcription factors at 
the center of placental disease gene modules and to model their 
in vivo involvement in placental pathways associated with mater-
nal or placental/fetal disease (Figure 2).
resUlTs
Placental study
Alterations in the Placental Transcriptome in Preterm 
Preeclampsia
Given that the pathogenesis of preeclampsia has been implicated 
to originate from the placenta, we first aimed to investigate pla-
cental transcriptomic changes leading to placental dysfunction 
TaBle 1 | Demographics of Hungarian women included in the placental 
microarray study.
groups controls for preterm Pe 
(n = 5)
Preterm Pe  
(n = 12)
Maternal age (years)b 31.6 (31.5–34.3) 30.3 (26.1–35)
Primiparitya 40 66.7





Systolic BP (mmHg)b 120 (120–120) 163 (160–170)c
Diastolic BP (mmHg)b 80 (70–80) 100 (100–101)c
Proteinuriaa 0 100c
Birthweight (g)b 1,990 (1,640–2,210) 1,065 (990–1,420)
Cesarean deliverya 100 100
BP, blood pressure; PE, preeclampsia.
aPercentage.
bMedian (interquartile range).
cp < 0.01.FigUre 2 | Flow-chart of experimental procedures. The placental study 
included extensive histologic, transcriptomic, epigenetic, and protein level 
investigations of the placenta to target the molecular pathways in the center 
of disease. Molecular changes were correlated with disease outcomes in 
both mothers and babies to uncover placental pathways affecting either 
maternal or fetal wellbeing. The maternal study included first trimester 
maternal blood proteomics and “virtual” liquid biopsy of the placenta to reveal 
blood factors of maternal or placental origin that can reflect disease 
conditions in early pregnancy. In the trophoblast study, hub transcription 
factors in placental gene modules separately associated with maternal or 
placental/fetal disease were investigated with various in vitro methods to 
model in vivo disease pathways.
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as well as regulatory networks involved in the pathologic 
pathways. The combined analysis of preterm preeclampsia cases 
and gestational age-matched controls (n = 17) in a Hungarian 
patient population (Table  1) in our placental microarray data 
(132) revealed 1,409 differentially expressed (DE) genes (Data S1 
in Supplementary Material), which are involved in fundamental 
cellular processes, including blood pressure (BP) regulation, 
apoptosis, development, hormone secretion, metabolism, 
homeostasis, and signaling (Figure 3A). DE genes included 137 
transcription regulatory genes and 38 predominantly placenta-
expressed genes. This latter set of genes (n =  164, Data S2 in 
Supplementary Material), which was defined by BioGPS micro-
array data (n =  153) or expression data from separate studies 
in the lack of BioGPS data (n =  11) (151–153), was enriched 
among DE genes in preeclampsia [odds ratio (OR)  =  3.4, 
p = 6.9 × 10−9]. This suggests that genes predominantly expressed 
by the placenta have pathologic and diagnostic significance in 
preeclampsia, a phenomenon indicated earlier by our targeted 
studies (153–155).
Subsequently, we investigated the genomic links among DE 
genes by searching for genomic regions associated with the 
observed placental transcriptomic changes. We found that Chr6 
(OR = 1.54, q = 1.6 × 10−3) and Chr7 (OR = 1.42, q = 0.02) were 
particularly affected by these gene expression changes (Data S3 
in Supplementary Material), while Chr19 (OR = 2.6, q = 0.02) 
was enriched in dysregulated transcription regulatory genes 
(Data S4 in Supplementary Material). Of interest, predominantly 
placenta-expressed genes were also enriched on Chr19 (OR = 2.5, 
q = 0.002) (Data S5 in Supplementary Material). Figure 3B shows 
the non-random genomic localization of DE genes in preterm 
preeclampsia and the pronounced gene dysregulation associated 
with Chr19. These results are consistent with the fact that Chr19 
harbors large transcription regulatory gene families (156), and 
probably reflect its regulatory role in placental/trophoblastic gene 
expression and their dysregulation in preeclampsia.
Alterations in Biological Processes and Regulatory 
Networks in Preterm Preeclampsia
Next, we aimed to identify functional links among DE genes by 
identifying gene co-expression network modules and hub tran-
scription regulatory genes driving differential expression in the 
modules. Weighted co-expression network analysis (WGCNA) 
was conducted among DE genes resulting in the assignment of 
these into four major modules, labeled as M1 (green, n = 506), 
M2 (red, n = 442), M3 (blue, n = 381), and M4 (orange, n = 74) 
(Figure 3C; Data S1 in Supplementary Material). Most predomi-
nantly placenta-expressed genes belonged to modules M1 (n = 22 
genes) and M2 (n =  12). Module M1 was enriched in down-
regulated genes (OR = 1.88, p = 2.59 × 10−8), while module M2 
was enriched in up-regulated genes (OR = 6.47, p = 2.2 × 10−16), 
suggesting the presence of distinct dysregulated gene-networks. 
Genes with predominant VT expression (14%) were mainly 
down-regulated, while genes with predominant EVT expression 
(9%) were mainly up-regulated even though both sets had the 
most members in module M1 (Figure 3D). These data suggested 
that the functions of both VT and EVT are strongly impacted in 
preterm preeclampsia, albeit in different ways.
Predominantly placenta-expressed genes, down-regulated in 
module M1, are regulators of fetal growth (CSH1, HSD11B2) 
(157, 158), metabolism (ESRRG) (159), estrogen synthesis (HSD17B1) 
(160), and immune functions (LGALS14) (153), some of which 
were reported to be down-regulated in preeclampsia (30, 91, 130, 
155, 161, 162). Within this module, ESRRG, POU5F1, and ZNF554 
transcription regulatory genes had the highest number of signifi-
cant correlations with predominantly placenta-expressed genes 
FigUre 3 | Placental transcriptomic changes in preterm preeclampsia. (a) The network of biological processes enriched among differentially expressed (DE) genes. 
Circle sizes relate to the number of genes involved in the biological processes; colors refer to p-values according to the color code. Groups of the most enriched 
biological processes were circled and labeled. (B) Circos visualization of DE genes in preterm preeclampsia (PE). The inner circle shows chromosomes; curved lines 
represent correlation (red: positive; blue: negative) between transcription regulatory genes and their targets; the second circle shows genomic location of 
predominantly placenta-expressed genes (black lines: non-DE; red or blue lines: up- or down-regulated); third and fourth circles show the locations of DE 
transcription regulatory genes and their targets, respectively with blue (down-regulated) and red (up-regulated) bars. The height of the bars represents the magnitude 
of expression changes. (c) Dysregulated placental gene expression was characterized by four major disease gene modules within DE genes, marked with different 
colors. The height plotted on the y-axis represents distance metric. Of 38 predominantly placenta-expressed genes (black vertical lines), 33 belonged to the M1 
(green, n = 22) and M2 (red, n = 11) modules. These modules were enriched in predominantly placenta-expressed genes and enriched in up-regulated (M2) or 
down-regulated (M1) genes marked under the modules with red or blue lines, respectively. (D) Pie charts depict the distribution of three gene sets among 
dysregulated genes or gene modules. Genes with similar expression in villous (VT) and extravillous trophoblast (EVT) had similar distribution among up- or 
down-regulated genes and in modules M1 and M2. Genes with up-regulation in VT compared to EVT were predominantly down-regulated in preeclampsia and 
positioned in module M1. Genes with up-regulation in EVT compared to VT were predominantly up-regulated in preeclampsia and positioned also in module M1.
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and, hence, deemed as hub factors (Figure S1A in Supplementary 
Material). Of note, these transcription factors have been impli-
cated in the regulation of stemness and differentiation (163, 164), 
pointing to the possible involvement of module M1 in the dys-
regulation of trophoblast differentiation in preterm preeclampsia. 
We selected ZNF554 for functional studies, since it belongs to the 
TaBle 2 | Demographics of American women included in the placental validation study.
groups controls for preterm Pe  
(n = 20)
Preterm Pe  
(n = 20)
Preterm Pe with sga (n = 20)
Maternal age (years)b 22 (20–28.5) 23.5 (21–27) 22.5 (19.5–30)
Primiparitya 20 40 25
Gestational age (weeks)b 32.3 (28.2–34.9) 31.4 (29.6–33.6) 31.8 (29.7–34.4)
Racea
Caucasian 5 10 10
African-American 95 90 90
Other 0 0 0
Systolic BP (mmHg)b 116 (110–125) 177 (166–187)c 171 (164–189)c
Diastolic BP (mmHg)b 65 (59–71) 105 (103–111)c 108 (94–118)c
Proteinuriab 0 3 (2–3)c 3 (3–3)c
Birthweight (g)b 1,635 (1,075–2,715) 1,488 (1,050–1,908) 1,173 (908-1,650)d
Birthweight percentileb 40.5 (31.9–53.4) 22.7 (18.3–32.9)d 6.7 (1–8.6)c
Cesarean deliverya 45 80d 75
groups controls for term  
Pe (n = 20)
Term Pe  
(n = 10)
Term Pe with sga  
(n = 10)
Maternal age (years)b 22 (21–32) 19 (19–35) 26.5 (19–31)
Primiparitya 15 40 10
Gestational age (weeks)b 38.6 (38–39.1) 39.1 (38.6–39.6) 38.4 (37.3–38.9)
Racea
Caucasian 15 0 0
African-American 80 100 100
Other 5 0 0
Systolic BP (mmHg)b 121 (111–134) 173 (165–178)c 169 (164–190)c
Diastolic BP (mmHg)b 70 (64–73) 106 (102–110)c 102 (97–104)c
Proteinuriab 0 3 (1–3)c 3 (1–3)c
Birthweight (g)b 3,215 (3,110–3,335) 3,123 (2,990–3,200) 2,405 (2,205–2,555)c
Birthweight percentileb 46 (37.2–63) 37.1 (28.5–48.8) 1.1 (1–3.5)c
Cesarean deliverya 55 40 20
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KRAB zinc finger family, crucial for early embryonic develop-
ment and differentiation (165), and it may regulate genes in its 
co-expression network involved in biological processes affected 
by preeclampsia, such as development, chromatin assembly, 
signaling, adhesion, migration, and metabolism (Figure S1B in 
Supplementary Material).
In module M2, FLT1, which expresses sFlt-1, the main driver 
of BP elevation in the terminal pathway of preeclampsia (56, 90), 
was up-regulated. Moreover, module M2 genes were strongly 
overrepresented (OR = 29.9, p = 6.54 × 10−95) among genes that 
had correlated expression with mean arterial pressure (MAP) 
(Data S6 in Supplementary Material), suggesting a key role for 
this module in promoting hypertension. Within this module, 
BCL6, BHLHE40, and ARNT2 had the highest correlation in 
gene expression with predominantly placenta-expressed genes, 
including FLT1 (Figure S1A in Supplementary Material). Of note, 
these transcription regulatory hub genes are involved in hypoxia 
response. ARNT2 heterodimerizes with hypoxia-response regula-
tor HIF-1α that is involved in trophoblast invasion and the patho-
genesis of preeclampsia (166–169), and ARNT2 is a key regulator 
for adaption to hypoxic conditions at high altitudes, where the 
incidence of preeclampsia is much higher (16%) than at low alti-
tude (170, 171). BHLHE40 links immune and hypoxia-induced 
pathways (172). BCL6, a gene previously found to be up-regulated 
in the placenta in preterm preeclampsia, represses trophoblast 
differentiation and is regulated by stress-activated protein kinase 
signaling pathways (135, 173, 174). Our co-expression analysis 
revealed an enrichment of biological processes, such as dif-
ferentiation, apoptosis, metabolism, signaling, and responses to 
stimuli including oxygen among genes co-expressed with BCL6 
(Figure S1C in Supplementary Material). Since BCL6 is a key 
player in inflammation and oxygen-driven regulation of cell fate, 
we selected this gene for functional studies along with ARNT2.
The Association of Gene Modules With Clinical 
Parameters
Next, to validate the microarray results on a larger patient popula-
tion (n = 100) comprised mostly of subjects of African-American 
origin presenting various phenotypes of preeclampsia (Table  2; 
Figure S2 in Supplementary Material), we selected 47 genes for 
qRT-PCR profiling of 100 placentas (Table  3), provided these 
genes were: (1) dysregulated genes with predominant placental and 
syncytiotrophoblastic expression, potentially encoding biomark-
ers; (2) dysregulated hub transcription regulatory genes that had 
a high co-expression with dysregulated, predominantly placenta-
expressed genes in modules M1 and M2; and (3) non-dysregulated 
genes with roles in trophoblast differentiation, trophoblast-specific 
gene expression, or the pathogenesis of preeclampsia.
TaBle 3 | Genes included in the placental qRT-PCR validation study.




hub Tr genes in 
modules (microarray)
Tr genes PPe genes De genes in preterm 
Pe (qrT-Pcr)
De genes in term 
Pe (qrT-Pcr)
ARNT2 Up M2 M2 Yes – Up –
BCL3 Up M1 – Yes – – Up
BCL6 Up M2 M2 Yes – Up –
BTG2 Down M2 – Yes – Down Down
CDKN1A Down M1 – – – – Up
CGB Up M4 – – Yes – Up
CLC Up M2 – – – Up Up
CLDN1 Down M1 – – – Down Down
CRH Up M2 – – Yes Up –
CSH1 – M1 – – Yes Down –
CYP19A1 – – – Yes Yes – –
DUSP1 Up M2 – – – Up –
ENG – – – – – Up Up
ERVFRDE1 – – – – Yes – –
ERVWE1 – – – – Yes – –
ESRRG Down M1 M1 Yes Yes Down –
FBLN1 Down M1 – – Yes – –
FLT1 Up M2 – – – Up Up
GATA2 – – – Yes – – –
GCM1 – – – Yes Yes Down –
GH2 – – – – Yes – –
HLF Down M1 – Yes – Down –
HSD11B2 Down M1 – – Yes – –
HSD17B1 Down M1 – – Yes Down Down
IKBKB Up M1 – – – – –
INSL4 Up M4 – – Yes – –
JUNB Up M2 – Yes – Up –
KIT Up M2 – – – Up –
LEP Up M2 – – Yes Up Up
LGALS13 – – – – Yes Down Down
LGALS14 Down M1 – – Yes Down Down
LGALS16 – – – – Yes – –
LGALS17A – – – – – – –
MAPK13 – – – – – – Up
NANOG – – – Yes – – –
PAPPA – – – – Yes – –
PAPPA2 Up M2 – – Yes Up Up
PGF – – – – Yes – –
PLAC1 Down M1 – – Yes Down –
POU5F1 Up M1 M1 Yes – – –
SIGLEC6 Up M2 – – Yes Up Up
TEAD3 – – – Yes Yes – Up
TFAM Down M3 – Yes – – Up
TFAP2A – – – Yes Yes – –
TPBG Up M2 – – – Up Up
VDR Up M2 – Yes – – –
ZNF554 Down M1 M1 Yes – Down Down
PE, preeclampsia; DE, differentially expressed; TR, transcription regulatory; PPE, predominantly placenta-expressed.
Identical dysregulation in the validation cohort as in the microarray cohort is depicted in bold font.
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As depicted in the heatmap representing qRT-PCR data for 
the 100 placentas and 47 genes (Figure  4A), validation data 
supported microarray experiments in terms of (1) differential 
expression of selected genes, (2) high correlation of genes within 
modules M1 and M2, and (3) separate dysregulation of modules 
M1 and M2 from each other. Comparison between preterm 
preeclampsia and gestational age-matched controls revealed 
that qRT-PCR data validated microarray results (differential 
or non-differential gene expression) for 33 of 47 genes (70%), 
and further confirmed the differential expression of four genes 
that were non-dysregulated in the microarray cohort (Table 3). 
As expected, the extent of changes in gene expression was less 
pronounced in term preeclampsia (Table 3; Figure 4C; Figure 
S3 in Supplementary Material). As a further confirmation, 
there was a strong correlation between qRT-PCR data as well 
as tissue microarray (TMA) and immunostaining results for 
selected proteins in module M2 (Figures 4C–E). The extent of 
dysregulation was larger in preterm phenotypes of preeclampsia 
than in term phenotypes, in agreement with the more severe 
placental pathology (44). Among transcription regulatory 
genes of module M1, HLF had strong down-regulation only in 
preterm preeclampsia while ZNF554 was expressed at a lower 
FigUre 4 | Gene modules associated with blood pressure (BP) and birthweight (BW). (a) Hierarchical clustering of qRT-PCR data obtained with 100 samples and 
47 genes. Pearson correlation was used for similarity analysis and average method for linkage calculation. Samples were colored according to patient groups and 
maturity status. M1 (green) and M2 (red) module genes and 34 of 60 samples from women with preeclampsia clustered together. (B) Association of gene expression 
with BP and BW. The significance p-values for these coefficients were plotted for all genes, colored according to module classification (black: not changed on the 
microarray). Filled circles represent predominantly placenta-expressed genes and dashed lines the significance threshold at p = 0.05. Seven of 9 genes related to 
BW belong to module M1, while 10 of 15 genes related to BP are from module M2. Gene expression (c) and protein immunostaining (D) of selected four genes in 
module M2 show similar patterns in the sub-groups of preeclampsia, and semi-quantitative immunoscorings validate gene expression data. Significant differences in 
preterm or term preeclampsia samples compared to gestational-age matched controls are shown with “*”. When the change with preeclampsia in preterm samples 
was different from that in term samples, a “+” marks such an interaction. Comparisons for all genes are available in Figure S3 in Supplementary Material. (e) 
Representative images of the same placenta from a preterm control (left, 29 weeks) and a patient with preterm preeclampsia associated with SGA (right, 31 weeks) 
are shown for the immunostainings (hematoxylin counterstaining, 40× magnification).
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level in all preeclampsia phenotypes (Figure S3 in Supplementary 
Material). Among the transcription regulatory genes in module 
M2, ARNT2, BCL6, and JUNB were highly expressed in preterm 
but not in term preeclampsia, suggesting that these might play a 
role only in the pathology of preterm cases (Figure 4C; Figure S3 
in Supplementary Material). Overall, these data reflect the het-
erogeneous placental pathology and the more severely affected 
pathways in preterm preeclampsia.
FigUre 5 | The timing of gene module dysregulation in preterm preeclampsia. (a) A database of 80,170 measurements published in 61 reports (35, 61, 82, 88, 
126, 178–233) was built for “virtual” liquid biopsy of the placenta in preterm preeclampsia with maternal blood levels of proteins with the highest expression in the 
placenta among all tissues [i.e. hCG, human placental lactogen (hPL), sEng, sFlt-1, and leptin]. Levels of these biomarkers in preterm preeclampsia were expressed 
as the percentage of control levels (dashed line) and were represented in scatter plots by different colors reflecting gene module classification. Based on qRT-PCR 
data, sEng belongs to module M2 (red). hPL (M1, green module) levels in preeclampsia were constantly below control levels during gestation, while the levels of 
module M2 biomarkers in preeclampsia had continuous elevation compared to control levels as a function of gestational age. (B) Analysis of first trimester data 
revealed the lower expression of all biomarkers in preeclampsia than in controls before the onset of maternal circulation, and the increasing expression of module 
M2 biomarkers in preeclampsia compared to controls after 12 weeks of gestation.
TaBle 4 | Demographics of Israeli women included in the maternal blood two-dimensional differential in-gel electrophoresis proteomics study.
groups controls for preterm Pe with sga 
(n = 5)
Preterm Pe with sga (n = 5) controls for term Pe 
(n = 5)
Term Pe  
(n = 5)
Maternal age (years)b 30 (24–31) 29 (27–37) 29 (27–34) 26 (23–32)
Primiparitya 40 20 80 40
Gestational age at blood draw (weeks)b 10 (9–11) 8 (8–9) 8 (8–9) 9 (8–10)
Gestational age at delivery (weeks)b 39.7 (38.6–40.0) 34.9 (29.3–35.3)d 38.7 (38.6–41.0) 38.1 (38.0–38.1)
Racea
Caucasian 100 100 100 100
African-American 0 0 0 0
Other 0 0 0 0
Systolic BP (mmHg)b 105 (104–110) 160 (150–165)c 110 (110–118) 150 (140–160)c
Diastolic BP (mmHg)b 60 (60–70) 100 (100–100)c 67 (63–68) 100 (90–100)c
Proteinuriab 0 4 (3–4)c 0 3 (3–4)c
Birthweight (g)b 2,955 (2,900–3,100) 1,720 (975–1,800)c 3,390 (3,270–3,600) 3,200 (3,150–3,210)
Cesarean deliverya 0 60c 60 40
BP, blood pressure; PE, preeclampsia; SGA, small-for-gestational age.
aPercentage.
bMedian (interquartile range).
cp < 0.05 when compared to corresponding controls.
dp < 0.001 when compared to corresponding controls.
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Because of the possible involvement of these two gene mod-
ules in distinct pathologic pathways, we correlated qRT-PCR data 
with maternal and fetal clinico-pathological indicators to further 
investigate their association (Figure  4B). This analysis showed 
that 7 of 9 genes related to the birthweight (BW) percentile were 
from module M1, while 10 of 15 genes related to BP were from 
module M2, confirming our observations with microarray data. 
Therefore, we decided to also refer to these as “M1-BW” and 
“M2-BP” modules. Of interest, the expression of most (9/14) 
M1 genes was negatively associated with the “maternal vascular 
malperfusion” score of the placenta, while the expression of most 
(10/14) M2 genes was positively correlated with this parameter 
(Data S7 in Supplementary Material). This observation fits well 
with the accepted concept that maternal vascular malperfusion 
of the placenta leads to oxidative stress (40, 41, 63, 175) and the 
increased placental expression of FLT1 (63).
Maternal study
Maternal Blood Reflects Gene Module Dysregulation 
in Preeclampsia
Next, we investigated whether placental gene module dysregula-
tion can be detected in maternal blood and whether liquid biopsy 
FigUre 6 | Maternal blood proteomic changes and their effect on differentially expressed (DE) genes in preterm preeclampsia. (a) The 19 DE maternal serum 
proteins in preterm preeclampsia identified by two-dimensional differential in-gel electrophoresis could be classified into functional groups relevant for preeclampsia 
pathophysiology. Asterisks denote proteins reported by others to have the same direction differential abundance in the first trimester in patients developing preterm 
preeclampsia (126, 143, 239–241). Dots denote immune proteins that multiple reaction monitoring assays identified to have differential abundance in preterm 
preeclampsia in the same direction. (B) The 19 DE serum proteins have connections to 121 DE placental genes, among which 48 belong to module M2. 
Angiotensinogen has more connections than other proteins (OR = 1.9, p = 4.9 × 10−5), and the most connections to module M2 genes (n = 35); 77 of 86 
connections of angiotensinogen have a directional effect toward the gene. Dots denote genes in connection to angiotensinogen found up-regulated in villous 
trophoblast (VT) upon treatment with first trimester serum from preeclamptic women. (c) Hierarchical clustering tree and heatmap representing differential placental 
gene expression in preeclampsia as in Figure 4a. The expression of the same genes (except IKBKB) was determined in primary VTs upon treatment with first 
trimester maternal serum. Serum from preeclamptic compared to control women induced the up-regulation of seven placental dysregulated genes (depicted with 
boxes) on the first and third days of VT differentiation, among which six were up-regulated in term and three in preterm preeclampsia. Stars depict significant 
changes, color bar encodes signed (up or down)-fold changes. Abbreviations: NA, not expressed; NT, not examined.
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can be used to determine when the module dysregulation occurs. 
To study the relationship between placental gene expression and 
maternal biomarker concentrations, we selected predominantly 
placenta-expressed genes with the most differential expression in 
modules M1 (CSH1) or M2 (LEP), and correlated their placental 
expression levels with concentrations of their secreted protein 
products (hPL and leptin) in maternal blood collected in both 
first (n = 12) and third trimesters (n = 19) in a Hungarian patient 
population. Positive correlations were found between placental 
gene expression and maternal blood protein concentrations for 
both biomarkers in both trimesters (Figure S4 in Supplementary 
Material), suggesting that certain proteins in the maternal 
circulation reflect the placental expression of their encoding 
genes throughout pregnancy.
To detect disease-associated protein signatures of placental 
dysfunction in maternal blood, similar to plasma DNA tissue 
mapping for noninvasive prenatal assessments (176, 177), we 
performed “virtual” liquid biopsy of the placenta in preterm 
preeclampsia (Figure S5 in Supplementary Material; Figure 5). 
We identified five genes with predominant placental expression, 
which have products extensively investigated in maternal blood 
in preterm preeclampsia or in all cases of preeclampsia dur-
ing all trimesters. From data of 61 reports (35, 61, 82, 88, 126, 
178–233), we built a database of 80,170 measurements in which 
TaBle 5 | Demographics of Hungarian women included in the maternal blood 
multiple reaction monitoring proteomics study.
groups controls for preterm Pe 
with sga (n = 10)
Preterm Pe with 
sga (n = 5)
Maternal age (years)b 29.7 (28.9–31.5) 34.7 (28.6–35.1)
Primiparitya 20 80
Gestational age at blood  
draw (weeks)b
12.6 (12.6–12.8) 12.4 (12.4–13.0)
Gestational age at delivery 
(weeks)b





Systolic BP (mmHg)b 124 (118–126) 170 (170–170)c
Diastolic BP (mmHg)b 75 (68–79) 100 (100–110)c
Proteinuria (g)b 0 3 (1–6)c
Birthweight (g)b 3,460 (3,308–3,623) 1,380 (790–1,450)c
Cesarean deliverya 30 100c





Than et al. Preclinical Pathways of Preeclampsia
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1661
preeclampsia data were expressed as a percentage of average levels 
in controls. Regarding biomarkers in module M1, we found hPL 
levels in preterm preeclampsia to be consistently below control 
levels throughout pregnancy. This is substantiated by the down-
regulation of another M1 biomarker, HSD17B1, in first trimester 
maternal blood (160), confirming a generalized down-regulation 
of M1 biomarkers in early pregnancy. By contrast, the levels of 
biomarkers in module M2 had constant elevation in preterm 
preeclampsia compared to controls during gestation. When 
analyzing only data collected in the first trimester, prior to the 
onset of maternal circulation to the placenta, levels of M1 and M2 
biomarkers were lower in women with preeclampsia compared to 
controls, while after 12 weeks of gestation, following the opening 
of the intervillous spaces to maternal blood flow, patients had 
increasing levels of M2 biomarkers in maternal blood compared 
to controls. These findings offer support for the conclusion that 
placental transcriptomic changes typical for preeclampsia in the 
third trimester are rooted in the first trimester.
Altered Maternal Serum Proteome in Preeclampsia
Next, we investigated the maternal serum proteome in early preg-
nancy in distinct phenotypes of preeclampsia and the potential 
effects of proteomic changes on the placental transcriptome. 
Comparing samples from women with preterm preeclampsia 
associated with SGA and their respective controls from an Israeli 
patient population (n = 10, Table 4), 19 DE protein spots were 
identified and investigated by mass spectrometry. According to 
public data, many of these proteins have a role in immune response, 
complement and coagulation cascades, lipid transport and metab-
olism, angiogenesis, BP regulation, and ion transport (Figure 6A, 
Data S8 in Supplementary Material). Comparing samples from 
women with term preeclampsia and their respective controls from 
this Israeli patient population (n = 10, Table 4), 14 DE protein 
spots could be identified (Figure S6A; Data S8 in Supplementary 
Material). Many of the proteins found in these spots are the 
same as those found in preterm preeclampsia or function in the 
same pathways. Of note, these pathways and the 26 differentially 
abundant proteins identified in term and preterm preeclampsia 
had mostly been implicated in a later stage of preeclampsia 
(43, 101, 120, 234–238). We concluded that there is a common 
dysregulation of the maternal serum proteome in term and 
preterm preeclampsia; however, the extent of changes is larger 
in the latter, in agreement with the more fulminant and early 
pathogenesis.
Supporting our findings, five studies (126, 143, 239–241) 
found proteins with differential abundance in preterm preec-
lampsia in the same direction as our two-dimensional differ-
ential in-gel electrophoresis (2D-DIGE) study (Figure 6A). We 
also collected maternal blood specimens in the first trimester 
from a Hungarian patient population (n = 15, Table 5), and 
measured the concentrations of 10 immune proteins in patients 
with preterm preeclampsia associated with SGA and matched 
controls using liquid chromatography–mass spectrometry 
multiple reaction monitoring (MRM). In spite of the difference 
between the methods and ethnic background, MRM identi-
fied 4 of these 10 proteins as having differential abundance in 
the same direction as in the 2D-DIGE study, supporting the 
early pro-inflammatory changes in the maternal proteome in 
preterm preeclampsia (Figure 6A; Data S9 in Supplementary 
Material). MRM and proteomic evidence published to date 
supported 37% (7/19) of the proteomic changes detected by 
2D-DIGE.
The In Silico Effects of Altered Maternal Serum 
Proteome on the Placenta
To reveal whether early proteomic changes in maternal blood 
may affect the placental transcriptome, placental DE genes with 
documented connections to DE proteins in maternal serum 
were identified by Pathway Studio. The 121 DE placental genes 
with connections to DE serum proteins in preterm preeclampsia 
were marginally over-represented by those from module M2 
(48/121, OR = 1.4, p = 0.057). Angiotensinogen had the largest 
number of connections to DE genes including FLT1 and LEP 
(n =  86, OR =  1.9, p =  4.9 ×  10−5). This protein also had the 
largest number of connections to module M2 genes (n =  35), 
followed by plasminogen (n = 11) and kininogen-1 (n = 9), all 
involved in BP regulation (Figure 6B). These data were supported 
by the “renin-angiotensin signaling” as being a top pathway 
(p = 1.28 × 10−4) among the 35 angiotensinogen-connected DE 
genes (Data S10 in Supplementary Material). Similar results were 
obtained when analyzing connections between 116 DE placental 
genes and DE serum proteins in term preeclampsia (Figure S6B 
in Supplementary Material).
Trophoblast study
The In Vitro Effects of an Altered Maternal Serum 
Proteome on the Trophoblast
Next, we aimed to study various factors implicated in the patho-
genesis of preeclampsia in trophoblast models to determine 
whether these may drive the observed placental transcriptomic 
changes. Since the results noted above suggested that maternal 
serum proteins can influence the placental transcriptome, we 
FigUre 7 | The effect of trophoblast differentiation on differentially expressed genes in preeclampsia. (a) Hierarchical clustering tree of expression data for 47 genes 
in 100 placental specimens was augmented with a heatmap representing differential gene expression in term or preterm subgroups of preeclampsia. (B) Primary 
villous trophoblast (VT) differentiation time series expression data for 47 genes were depicted with a heatmap representing differential gene expression in each time 
point (days 1–7) compared to day 0. (c) Maximum expression values in the VT differentiation time series were presented alongside with maximum expression values 
in the placenta in preterm or term preeclampsia. Comparative visualization revealed the opposite-direction differential regulation of 17 genes in preeclampsia 
compared to VT differentiation as depicted with black boxes. Among these genes, 15 had this behavior in preterm preeclampsia and 9 in term preeclampsia 
(p = 0.057). In (a–c), stars depict significant changes, color bar encodes signed (up or down)-fold changes. Abbreviations: NA, not expressed; NT, not examined.
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first measured the effects of maternal blood from early preg-
nancy on trophoblastic gene expression. We treated primary 
VTs during differentiation with first trimester sera from women 
with preterm preeclampsia or normal pregnancy, and analyzed 
the expression of genes included in the placental validation 
study. Serum from preeclamptic women compared to controls 
induced up-regulation of seven placental DE genes on the first 
and third days of trophoblast differentiation, including FLT1 and 
LEP (Figure 6C). Among these, six genes were up-regulated in 
the placenta in term and three in preterm preeclampsia. These 
results support in silico findings and suggest that maternal serum 
factors can up-regulate FLT1 and may induce the terminal 
pathway.
The Effects of Altered VT Differentiation
Next, we examined whether disturbance in VT differentiation 
may be reflected in the placental gene expression signature in 
women with different preeclampsia phenotypes. Since there 
FigUre 8 | The effect of O2 levels, BCL6 and ARNT2 overexpression on differentially expressed genes in preeclampsia. (a) Hierarchical clustering tree and heatmap 
representing differential placental gene expression in preeclampsia. (B) The overexpression of ARNT2 or BCL6 in normoxic BeWo cells induced the dysregulation of 
three or five genes dysregulated in preeclampsia, respectively (boxed). (c) Hypoxia induced the dysregulation of five genes in BeWo cells also altered in 
preeclampsia. Hypoxia combined with ARNT2 or BCL6 overexpression led to the dysregulation of a large number of genes. (D) Ischemia induced the dysregulation 
of three genes in BeWo cells similar to preeclampsia. Ischemia combined with ARNT2 or BCL6 overexpression led to the dysregulation of 11 genes similar to 
preeclampsia. (c,D) Represents comparisons of gene expressions between hypoxia/ischemia vs. normoxia. In (a–D), stars depict significant changes, “O” depicts 
“overexpressed,” color bar encodes signed (up or down)-fold changes. Black boxes depict genes with similar expression changes in vitro as in the placenta in 
preeclampsia. Abbreviations: NA, not expressed; NT, not examined.
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were no (n =  46) or subtle (n =  2) gestational age-dependent 
differences in the expression of selected target or housekeeping 
genes in third trimester control placentas in our microarray 
study (132), the comparison of placentas and trophoblasts 
from various gestational ages was deemed to be valid. Thus, we 
performed qRT-PCR profiling of primary VTs during 7  days 
of differentiation to reveal the dynamics in the expression of 
genes (Figure 7B), which we similarly profiled in the placenta 
(Figure  7A). We determined whether maximum expression 
change of selected genes during VT differentiation compared to 
day 0 inversely correlated with their maximum expression change 
in different preeclampsia phenotypes. We found that this was the 
case for 17 genes (Figure 7C), suggesting the delay or inhibition 
of VT differentiation-related expression change of these genes in 
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preeclampsia. Among these 17 genes, 15 showed this behavior 
in preterm and 9 in term preeclampsia, suggesting that VT dif-
ferentiation problems are more pronounced in preterm than in 
term preeclampsia (p = 0.057).
The Impact of Hypoxia, Ischemia, and 
Overexpression of BCL6 and ARNT2 on the 
Trophoblast
Subsequently, we tested how other factors implicated in pre-
eclampsia pathogenesis, namely physiologic hypoxia (2% O2) 
(167) or alternating hypoxic (1% O2) and normoxic (20% O2) 
conditions (ischemia) (40, 41, 242), in combination with the 
overexpression of hub transcription regulatory factors, may 
affect trophoblastic gene expression in a widely used BeWo cell 
trophoblast model. Two percent O2 induced the dysregulation of 
only five genes, including LEP and FLT1, from the set of genes 
investigated in the placenta in preterm preeclampsia (Figure 8C), 
while alternating O2 concentrations induced the dysregulation of 
only three genes (Figure 8D). Since hypoxia or ischemia alone 
did not induce similar transcriptomic changes in BeWo cells 
as seen in the placenta in preeclampsia, we examined how the 
overexpression of hub transcription regulatory genes in module 
M2 may modify the effects of these two conditions. Of note, 2% 
O2 combined with ARNT2 or BCL6 overexpression led to the 
dysregulation of a large number of genes (Figure 8C). There were 
9 genes (6 in the M2 and 3 in the M1 modules) dysregulated 
in BeWo cells, including FLT1, ARNT2, and ZNF554, similar 
to preeclampsia. Alternating O2 concentrations combined with 
ARNT2 or BCL6 overexpression led to the dysregulation of 11 
genes (5 in the M2 and 3 in the M1 modules), including LEP, 
FLT1, and ENG, similar to preeclampsia (Figure 8D). However, 
ARNT2 or BCL6 overexpression at normoxic conditions did 
not lead to substantial gene expression changes (Figure  8B), 
underlining the importance of gene–environment interactions. 
A permutation test showed that BCL6 overexpression in ischemia 
mimicked overall expression changes of module M1 and M2 
genes in preterm preeclampsia, while ARNT2 overexpression 
in ischemia (and also in hypoxia) mimicked the up-regulation 
of module M2 genes in term and preterm preeclampsia (Data 
S11 in Supplementary Material). Since BCL6 overexpression 
up-regulated ARNT2 both in ischemia and hypoxia but not 
vice versa, we propose that BCL6 is upstream of ARNT2. The up-
regulation of these two transcription regulatory genes sensitize 
the trophoblast to ischemia, leading to the early dysregulation 
of modules M1 and M2, thus promoting preterm preeclampsia 
(Figure S7 in Supplementary Material).
Since none of the investigated conditions could up-regulate 
BCL6, we wondered whether BCL6 overexpression might have 
an epigenetic background. Treating BeWo cells with 5-azaciti-
dine down-regulated BCL6, supporting that its expression is 
regulated by DNA methylation in the trophoblast (Figure S8 in 
Supplementary Material). Of note, a recent study described the 
first intron of BCL6 to be key in its overexpression in Burkitt 
lymphoma via altered DNA methylation (243). The Human 
Reference Epigenome Mapping Project revealed a differentially 
methylated region (DMR) in this intron in H1 embryonic stem 
cells as well as trophoblastic and neuronal cells derived from H1 
cells, suggesting that this DMR may be differentially methylated 
in the trophoblast compared to other cells. To address whether 
this intronic region may be affected in the trophoblast in 
preeclampsia, we investigated DNA methylation in this region 
in primary VTs compared to cord blood cells collected from 
the same normal pregnancies. Bisulfite sequencing showed 
that Chr3:187,458,083-187,458,651 and Chr3:187,460,304-
187,460,374 regions contain 12 hypermethylated CpGs in the 
trophoblasts compared to cord blood cells (Figures S8 and S9 in 
Supplementary Material). Further, we tested DNA methylation 
in this region in 100 placentas with qRT-PCR data including 
patients with preeclampsia after laser capturing VTs. Three CpGs 
(Chr3:187,458,095, Chr3:187,458,163, and Chr3:187,458,327) 
were differentially methylated in preeclampsia (Figure S10 in 
Supplementary Material), of which CpG Chr3:187,458,163 
was differentially methylated in preterm preeclampsia, sug-
gesting that this CpG may have a role in BCL6 dysregulation in 
preeclampsia.
The Effects of ZNF554 Down-Regulation in VTs
Next, we were interested in how the dysregulation of module M1 
genes may play a role in preeclampsia pathology. Among hub genes 
of this module, ZNF554 was of most interest due to the biological 
processes enriched in its co-expression network (Figure S1B in 
Supplementary Material), and also to its potential placenta- and 
preeclampsia-related regulation by transposable elements. This 
hypothesis was based on the fact that insertion of transposable ele-
ments into regulatory regions can lead to transcriptional changes, 
especially in the placenta (155, 244–247), and that the 5′ flanking 
region of ZNF554 contains many LTR10A copies which had top 
enrichment among module M1 genes (OR = 17.4, p = 1.27 × 10−7; 
Data S12 in Supplementary Material). Of note, LTR10A drives 
placenta-specific expression of NOS3 (248), and it may also have a 
similar effect on ZNF554. Indeed, ZNF554 had the highest expres-
sion in the placenta in comparison to 47 other human tissues, 
which mostly had negligible ZNF554 expression (Figure 9A).
Subsequent in situ hybridization (Figure 9B) and immunostain-
ing (Figure 9C) of first and third trimester placentas of women with 
a normal pregnancy showed dominant ZNF554 expression in the 
syncytiotrophoblast but not in the villous cytotrophoblast. Thus, 
we investigated ZNF554 expression during VT differentiation, in 
which it was up-regulated similar to CSH1 (Figure 9D), supporting 
that ZNF554 expression is developmentally regulated in VTs. Of 
interest, ZNF554 immunostaining was faint in the syncytiotropho-
blast in preeclampsia compared to controls (Figures  9E,F). To 
characterize the loss of syncytiotrophoblastic ZNF554 function, 
we silenced ZNF554 in BeWo cells. At 74% ZNF554 knock-down 
(p = 5.24 × 10−6) (Figure 9G), decreased nuclear and cytoplasmic 
ZNF554 immunostaining was found (Figure  9H). Microarray 
analyses of ZNF554-silenced cells revealed 123 DE genes (Data 
S13 in Supplementary Material) including 9 DE placental genes 
in preeclampsia, and the dysregulation of the “glycolysis/gluco-
neogenesis” pathway (OR = 7.8, q = 0.06) as well as 18 molecular 
functions including “RNA binding” (down) and “activin bind-
ing” (up) (Figure 9I; Data S14 in Supplementary Material). The 
up-regulation of FSTL3 was confirmed by qRT-PCR (2.7-fold, 
p < 0.001) (Figure 9J). FSTL3 encodes a secreted glycoprotein that 
FigUre 9 | ZNF554 down-regulation in the villous trophoblast (VT) in preeclampsia. (a) Tissue qRT-PCR array revealed the highest ZNF554 expression in the 
placenta among 48 human tissues. Color code depicts gene expression levels relative to that of the placenta (100%). (B) In situ hybridization of a third trimester 
control placenta (GW29) and (c) immunohistochemistry of a first trimester placenta (GW12) shows mainly syncytiotrophoblastic ZNF554 expression (hematoxylin 
counterstaining, 1,400 and 400× magnifications, respectively). Black or white arrowheads depict syncytiotrophoblast or cytotrophoblast, while black arrow depicts 
fetal endothelium, respectively. (D) qRT-PCR revealed that ZNF554 expression is up-regulated during VT differentiation in parallel with CSH1. (e,F) ZNF554 
immunopositivity was faint in the syncytiotrophoblast in preeclampsia [(F), GW35] compared to gestational-age matched controls [(e), GW36] (hematoxylin 
counterstaining, 400× magnifications). Arrow and arrowhead depict syncytiotrophoblast and villous endothelium, respectively. (g) ZNF554 mRNA expression was 
74% lower in ZNF554-silenced BeWo cells compared to controls used for the microarrays (p = 5.24 × 10−6). (h) Nuclear and cytoplasmic ZNF554 
immunofluorescence decreased in BeWo cells treated with ZNF554 siRNA compared to control cells (3,500× magnifications). (i) Molecular functions and one Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway (glycolysis/gluconeogenesis) affected in ZNF554-silenced BeWo cells. Colors denote the proportions of 
up- or down-regulated genes (red: >0.5 up-regulated; blue:>0.5 down-regulated; black: 0.5–0.5 up- and down-regulated). Letter sizes represent the minus log10 of 
p-values of the given functions or pathway. (J) qRT-PCR validated FSTL3 up-regulation (2.7-fold, p < 0.001) in BeWo cells upon ZNF554 knock-down.
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inactivates activin and other TGFβ ligands (249). It is involved in 
the regulation of EVT invasion (250, 251) and its placental up-
regulation is associated with low BW in preeclampsia (252). This 
finding confirms that the dysregulation of ZNF554 may have key 
downstream effects on the pathogenesis of preeclampsia.
The Effects of ZNF554 Down-Regulation in EVTs
We supposed that ZNF554 may also affect EVTs, since its 
expression in EVTs was detected in first and third trimester 
maternal decidua (Figures  10A–D), and ZNF554-positive 
intraluminal and endovascular trophoblasts were found in the 
wall of transformed spiral arteries (Figure  10B). In preterm 
preeclampsia, ZNF554 immunostaining of EVTs was weaker 
than in controls (Figures  10C,D). To characterize the loss of 
ZNF554 function in EVTs, we silenced ZNF554 in trophoblas-
tic HTR8/SVneo cells (253). At 87% knock-down (p < 0.001) 
(Figure 10E), we observed decreased nuclear and cytoplasmic 
ZNF554 immunostaining (Figure  10F). Microarray analysis 
FigUre 10 | ZNF554 down-regulation in extravillous trophoblasts (EVTs) in preeclampsia. (a) EVTs in trophoblastic columns and (B) endovascular and intraluminal 
trophoblasts in the myometrium were immunostained for cytokeratin-7 (left) and ZNF554 (right). Arrows depict the direction of trophoblast invasion, black and white 
arrowheads point to EVTs in the wall and lumen of the spiral artery, respectively (serial sections, hematoxylin counterstaining, 200× magnifications). ZNF554 
immunostaining in EVTs  (arrowheads) and syncytiotrophoblast (arrows) was weaker in (D) preeclampsia than in (c) controls (serial sections, hematoxylin 
counterstaining, 200× magnifications). (e) ZNF554 mRNA expression decreased to 13% upon knock-down (p < 0.001), (F) ZNF554 immunofluorescence was 
weaker in the nucleus and cytoplasm of ZNF554-silenced (left) than of control (right) HTR8/SVneo cells (3,500× magnifications). (g) The dysregulation of selected 
genes upon ZNF554 knock-down was confirmed by qRT-PCR. (h) Plasminogen activator inhibitor-1 (PAI-1 / SERPINE1) and TIMP-3 proteins were increasingly 
secreted from ZNF554-silenced cells. (i) ZNF554-silenced cells had remarkably decreased invasive (left) and migratory (right) characteristics. O2 concentrations are 
shown below the bars.
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of ZNF554-silenced cells showed 185 DE genes (Data S15 in 
Supplementary Material) including 18 DE placental genes 
in preeclampsia. Gene ontology (GO) analysis revealed 16 
molecular functions dysregulated, including “cyclin-dependent 
protein kinase regulator activity,” “metalloendopeptidase 
inhibitor activity,” and “insulin-like growth factor binding.” 
The 67 enriched biological processes included “regulation of 
growth,” “smooth muscle cell migration,” “smooth muscle cell-
matrix adhesion,” and “response to oxygen levels,” all relevant 
to trophoblast invasion and placental pathology of preeclampsia 
(Data S16 in Supplementary Material).
qRT-PCR confirmed the dysregulation of eight DE genes. Two 
genes (CDKN1A, STK40) are involved in the regulation of cell pro-
liferation and differentiation (254, 255), and proliferation assays 
showed that ZNF554 knock-down decreased cell proliferation in 
HTR8/SVneo cells slightly after 48 h (−14%, p = 0.02) (Figure S11 
in Supplementary Material). Six genes (FSTL3, ITGB5, MYL12A, 
SDC1, SERPINE1, and TIMP3) encode proteins involved in cell 
adhesion, migration, invasion, and angiogenesis (Figure  10G). 
Since EVTs move through an environment with changing O2 
levels, we used O2 concentrations for conditions relevant for 
endovascular (8%) and interstitial (2%) trophoblast invasion 
FigUre 11 | The effect of trophoblastic DNA methylation on ZNF554 expression and clinical parameters in preeclampsia. (a) Increased ZNF554 expression in 
BeWo cells upon treatment with 5-azacitidine (5-AZA) irrespective of forskolin (FRSK) co-treatment. (B) Upper three lanes: whole genome bisulfite sequencing data 
of ZNF554 5′ flanking region from the Human Reference Epigenome Mapping Project. H1 ESC, H1 embryonic stem cell; HBDT, H1 BMP4-derived trophoblast; and 
HDNP, H1-derived neuronal progenitor. Lower three lanes: bisulfite sequencing data from this study. Abbreviations: CB, cord blood cell; CT, cytotrophoblast; ST, 
syncytiotrophoblast. Red boxes: AluY and AluSq2 are heavily methylated in cord blood cells and hypomethylated in trophoblasts. Red arrow: CpG Chr19:2,818,823. 
(c) CpG Chr19:2,818,823 was differentially methylated in trophoblasts in preterm preeclampsia ± SGA. (D) Correlation was observed between Chr19:2,818,823 
CpG methylation and ZNF554 expression, maternal vascular malperfusion score of the placenta, and birthweight percentile.
17
Than et al. Preclinical Pathways of Preeclampsia
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1661
besides standard cell cultures (20%). The effect of ZNF554 knock-
down was significant regardless of O2 levels on four genes (ITGB5, 
MYL12A, SERPINE1, and TIMP3), while there was an interaction 
between O2 levels and ZNF554 silencing on two genes (FSTL3 and 
SDC1) (Figure 10G).
The up-regulation of SERPINE1 (PAI-1) and tissue inhibitor 
of metalloproteinases-3 (TIMP-3) was also confirmed at the pro-
tein level in supernatants of ZNF554-silenced cells (Figure 10H). 
Both proteins have an inhibitory function on trophoblast migra-
tion and invasion (250, 256, 257), and TIMP-3 is the major tissue 
metalloproteinase inhibitor at the maternal–fetal interface, which 
is up-regulated in preeclampsia (106, 258, 259). These results 
suggested that ZNF554-silenced cells have reduced migratory 
and invasive functions. Indeed, functional assays revealed that 
ZNF554 silencing had a strong inhibitory effect on trophoblast 
migration (p = 1.9 × 10−10) regardless of the O2 concentration, 
and also on invasion (p < 0.001), especially at 2% O2 concentra-
tion (Figure 10I). These data corroborated that ZNF554 supports 
trophoblast invasion via modulating a set of key genes that are 
involved in this process.
DNA Methylation-Mediated Trophoblastic ZNF554 
Down-Regulation in Preeclampsia
We wondered whether placental ZNF554 down-regulation might 
have an epigenetic background, given that the ZNF554 flanking 
region contains several transposable elements, including several 
Alus, which are generally hypomethylated in germ cells and 
the placenta (260, 261), while their hypermethylation leading 
to altered gene expression may be detected in preeclampsia 
(262, 263). Thus, the down-regulation of ZNF554 expression in 
the placenta of patients with preeclampsia may also be reflected 
in the DNA methylation of the transposable elements in its 5′ 
flanking region.
The treatment of BeWo cells with 5-azacitidine increased 
ZNF554 expression, showing the role of DNA methylation in 
trophoblastic ZNF554 regulation (Figure 11A). The subsequent 
search in the Human Reference Epigenome Mapping Project data 
revealed a DMR located in the AluY, which was hypomethyl-
ated in H1 embryonic stem cells and H1-derived trophoblasts 
compared to H1-derived neuronal cells (Figure 11B). This was 
of interest, since AluY is a retrotransposon evolved recently in 
primates, and its differential DNA methylation supports the 
expression of other gene transcripts in the placenta compared to 
somatic tissues (264). These data prompted us to investigate the 
DNA methylation in this genomic region in primary VTs and 
cord blood cells collected from the same normal pregnancies. In 
fact, bisulfite sequencing showed that the AluY, similarly to the 
AluSq2, is heavily methylated in cord blood cells compared to 
the hypomethylated trophoblast, suggesting its importance in the 
developmental regulation of ZNF554 expression (Figure  11B; 
Figure S12 in Supplementary Material).
Further, we tested DNA methylation in this region in 100 pla-
centas with qRT-PCR data, including patients with preeclampsia 
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after laser capture of the VTs. Bisulfite sequencing of the tropho-
blastic DNA revealed four CpGs on AluY (Chr19:2,818,823, 
Chr19:2,818,864, Chr19:2,818,868, and Chr19:2,818,876) 
hypomethylated in controls but hypermethylated in preterm 
preeclampsia, with highest methylation in cases associated 
with SGA (Figure 11C; Figure S13 in Supplementary Material). 
Importantly, we found correlations between Chr19:2,818,823 
CpG methylation and ZNF554 expression (R = −0.30, p = 0.04), 
maternal vascular underperfusion score of the placenta (R = 0.36, 
p = 0.03), and BW percentile (R = −0.41, p < 0.01) (Figure 11D). 
These data collectively provide evidence that the hypermethyla-
tion of certain CpGs in AluY in the trophoblast may result in low 
ZNF554 expression, impaired trophoblast invasion, preeclampsia, 
and fetal growth restriction.
DiscUssiOn
The placenta has a key role in the pathogenesis of the terminal path-
way of preeclampsia, which may be triggered by discrete disease 
pathways at early stages of pregnancy, leading to the development 
of different preeclampsia phenotypes. In this study, an integrated 
systems biology approach was employed to gain insights into 
these complex pathways, given that this strategy offered the ulti-
mate analytic solution to investigate and understand the complex 
disease pathways of the syndrome of preeclampsia (265–268). We 
incorporated “omics,” clinical, placental, and functional data from 
patients with distinct phenotypes of preeclampsia. We employed 
molecular network-based approaches to identify networks and 
modules of genes or proteins that are perturbed in the placenta 
and the maternal circulation of women with preeclampsia.
Our placental transcriptomics study identified 1,409 DE 
genes involved in many biological processes (e.g. BP regulation, 
apoptosis, development, hormone secretion, metabolism, and 
signaling) that were previously implicated in the pathogenesis of 
preterm preeclampsia by other placental transcriptomics stud-
ies (105, 110, 111, 113, 114, 116, 117, 122, 123, 125, 127, 128, 
130, 131, 134, 137, 269–272). Despite the differences in patient 
populations, design, or methodologies between these studies, 
many DE genes on our list have also been found by other groups. 
Indeed, from the 40-gene meta-signature that characterized 
the significant intersection of DE genes from independent pla-
cental gene signatures in preeclampsia in the meta-analysis of 
Kleinrouweler et al. (135), our microarray and qRT-PCR studies 
found 26 (65%) to be DE in preterm preeclampsia. Of note, 16 
of these 26 genes belong to module M2, while only six to the M1 
module. This supports our observation that the dysregulation of 
module M2 is associated with BP elevation, the maternal disease 
condition required for patient inclusion into these studies. The 
weaker involvement of module M1 genes in the meta-signature 
may reflect the heterogeneity of preeclampsia transcriptomics 
studies regarding fetal (growth restriction) and placental disease 
conditions. Our microarray study was homogeneous for preterm 
preeclampsia cases with low BW and placental disease, while only 
a couple of other studies had this rigor. To overcome the incon-
sistency of smaller placental transcriptomics studies, Leavey 
et  al. (140, 142) employed advanced bioinformatics methods 
to aggregate microarray datasets across multiple platforms to 
generate large datasets of patient samples. Unsupervised cluster-
ing of these datasets revealed three distinct molecular subclasses 
of preeclampsia. Among these, the “canonical” subclass, which 
is associated with the differential expression of our module M2 
genes, was characteristic for preterm preeclampsia and consistent 
with stress response to poor oxygenation, further supporting our 
findings. However, our discovery on the two major dysregulated 
placental disease gene modules and their hub transcription regu-
latory genes, separately associated with maternal or fetal disease 
pathways, are novel (Figure 12).
Functional assays on hub transcription factors of these two 
disease gene modules demonstrated that ZNF554 (M1) down-
regulation leads to impaired trophoblast invasion, while BCL6 
and ARNT2 (M2) overexpression sensitizes the trophoblast to 
ischemia, which are hallmarks in the pathogenesis of preterm 
preeclampsia. In the “ZNF554” pathway, hypermethylation of AluY 
in the ZNF554 5′ flanking region inhibits gene expression, leading 
to impaired trophoblast invasion, placental vascular malperfusion, 
and low BW. In the “BCL6-ARNT2” pathway, which is activated 
only in preterm preeclampsia, ischemic stress of the trophoblast 
coupled with BCL6 and ARNT2 overexpression increases FLT1 
expression. This then eventually promotes the anti-angiogenic 
state, hypertension (37, 56, 57, 61, 62, 83), and the early onset of 
this syndrome (Figure S7 in Supplementary Material).
The perturbed placental disease gene modules in preterm 
preeclampsia can be detected by liquid biopsy in maternal blood 
in the early stages of pregnancy. Indeed, we detected the down-
regulation of M1 and M2 disease gene module biomarkers in these 
patients during the first trimester. Of interest, the up-regulation 
of module M2 biomarkers can be detected after the establishment 
of maternal circulation in the intervillous space. These findings 
support the observation that placental transcriptomic changes, 
typical for preterm preeclampsia observed in the third trimester, 
are rooted in the first trimester. The positive correlation of gene 
expression in module M1 with BW and in module M2 with BP 
suggests that M1 genes may be biomarkers for placental and fetal 
growth and development while M2 genes can serve as biomarkers 
for placental stress.
First trimester maternal blood proteomics uncovered the 
altered abundance of proteins of the renin–angiotensin and 
immune systems as well as complement and coagulation cascades 
in patients who subsequently developed both preterm and term 
preeclampsia. The same proteins and pathways were found to be 
dysregulated in maternal blood in later stages of preeclampsia by 
other proteomics studies (108, 115, 118–120, 126, 129, 133, 136, 
138, 139, 143); however, ours is the first revealing their dysregula-
tion at an earlier stage of pregnancy when there is no or minimal 
direct connection between the placenta and the maternal circula-
tion (273).
From these dysregulated maternal serum proteins, in silico 
analysis pointed to candidates, which may drive trophoblastic 
transcriptomic changes, and corroborated earlier findings 
on angiotensinogen/angiotensin II in driving hypertension 
indirectly through FLT1 up-regulation in addition to its direct 
effects (91, 274). Moreover, in vitro functional assays revealed 
that altered maternal serum proteome in the first trimester can 
affect the trophoblastic transcriptome and up-regulate FLT1. 
FigUre 12 | Pathologic pathways in preeclampsia. Maternal pathways: alterations in the maternal blood proteome, including systemic inflammatory changes, can be 
observed in both preterm and term preeclampsia before the maternal circulation of the placenta has been established, supporting the observation that maternal factors 
have a key role in triggering early disease pathways. Later, these alterations can induce trophoblastic functional changes leading to the up-regulation of module M2 
genes, the overproduction of sFlt-1, and an anti-angiogenic state through a trajectory that does not necessarily affect fetal growth. Placental pathways: altered 
differentiation of the trophoblast leads to the dysregulation of module M1 genes and hub factors in module M2. The down-regulation of ZNF554 and module M1 genes 
involved in the regulation of fetal growth and metabolism imply impaired villous trophoblast (VT) functions besides abnormal extravillous trophoblast (EVT) invasion. The 
up-regulation of the BCL6-ARNT2 pathway sensitizes the trophoblast to ischemia and increases FLT1 expression after the maternal circulation to the placenta has been 
established. These changes are observed only in preterm preeclampsia, suggesting that this placental pathway promotes the early development of preeclampsia. The 
interplay of these molecular pathways leads to the complex pathogenesis of preeclampsia. Abbreviations: RAS, renin-angiotensin system; SGA, small-for-gestational age.
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This is in agreement with reports indicating that maternal 
blood factors in preeclampsia can induce trophoblastic soluble 
endoglin overexpression and the development of preeclampsia-
like symptoms in mice (85, 275).
Remarkably, most of the dysregulated maternal serum 
proteins in the first trimester in both preterm (11 of 19) 
and term (7 of 14) preeclampsia are implicated in immune 
functions (Figure  6; Figure S6 in Supplementary Material), 
suggesting a critical role for immune pathways and inflam-
mation in the early pathogenesis of both phenotypes of 
preeclampsia. This is consistent with clinical, epidemiological, 
and immunological evidence showing that: (1) preeclampsia 
has multiple risk factors (e.g. dyslipidemia, hypertension, 
insulin resistance, and obesity) characterized by heightened 
inflammation (29, 276); (2) the combination of inhibitory 
decidual NK (dNK) cell killer immunoglobulin-like receptor 
and the fetal HLA-C2 genotype increases the susceptibility to 
preeclampsia due to the loss of activating interactions between 
trophoblasts and dNK  cells at early stages of placentation 
(168, 277–283); (3) an altered local immune regulation and a shift 
toward the pro-inflammatory macrophage phenotype promotes 
a pro-inflammatory milieu in the maternal decidua in preeclamp-
sia (284, 285); (4) an imbalance between Th1/Th2/Th17/Treg 
cells in preeclampsia leads to failure of maternal–fetal tolerance 
mechanisms (286–289); and (5) complement system activation 
in preeclampsia leads to the activation of innate immune cells 
and placental damage (101, 234, 236, 237, 290–292). The role 
of inflammation in early preeclampsia disease pathways is also 
supported by in vivo studies showing that bacterial endotoxin 
administration to pregnant rats induces placentation defects 
and symptoms consistent with preeclampsia (293–298).
Overall, our data show that there are distinct maternal and 
placental disease pathways, and their interaction influences the 
clinical presentation of preeclampsia. The activation of maternal 
disease pathways can be detected in both preterm and term 
preeclampsia earlier and upstream of placental dysfunction, not 
only downstream as described before (43), and distinct placental 
disease pathways are superimposed on these maternal pathways. 
This is a paradigm shift in our understanding of preeclampsia, 
which in agreement with epidemiological studies (25, 31) war-
rants for the central pathologic role of preexisting maternal 
diseases or perturbed maternal–fetal–placental immune interac-
tions in preeclampsia.
The superimposed placental disease pathways differ between 
preterm and term preeclampsia. For preterm preeclampsia, 
our functional data suggest that placental disease pathways 
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are partly originated from altered trophoblast differentiation, 
which is followed by trophoblastic stress, induced by perturbed 
maternal blood proteome factors and/or ischemia after the 
onset of maternal circulation to the placenta. Our data are con-
sistent with recent views indicating that defects in trophoblast 
proliferation, differentiation, invasion, and plugging are associ-
ated with defective decidualization (299), decidual inflamma-
tion (300), and the disturbance in endometrial-trophoblast 
dialog during the peri-conception (301) period. Abnormal 
trophoblast invasion and plugging will subsequently lead to 
the aberrant onset of maternal circulation (273) and malperfu-
sion, causing placental oxidative stress in preterm preeclampsia 
(175, 273, 302). On the other hand, maternal disease pathways 
induce mainly placental dysfunction without maldevelopment 
in term preeclampsia. This is substantiated by the differences 
observed in the maternal proteome, placental transcriptome, 
and trophoblastic DNA methylation between term and preterm 
preeclampsia in our study. Moreover, this is also consistent 
with the major differences between these two preeclampsia 
phenotypes in etiology (31), placental histopathology (28, 33, 
44–46), and stress levels (303) as well as clinical presentation 
(2, 25, 26, 29, 304).
Our findings are very timely in the light of recent clinical 
research showing that the administration of aspirin before 
16 weeks of gestation to pregnant women at risk for preeclampsia 
prevents the preterm phenotype of this syndrome (24, 305–309). 
Thus, the anti-inflammatory and anti-platelet actions of aspirin 
(308–311) may ameliorate the early pro-inflammatory disease 
pathways leading to placental maldevelopment in preterm preec-
lampsia. Based on our discovery of these novel disease pathways 
and their hub molecules, we propose a “molecular phase” of 
preeclampsia (Figure  12), where early pathologic events can 
already be detected by maternal blood biomarkers, offering non-
invasive diagnostics of maternal and placental disease pathways. 
Biomarkers of these disease pathways may open new venues for 
the molecular characterization of patients destined to develop 
preeclampsia, using multi-biomarker profiles that support 





Study Groups and Clinical Definitions
Placental tissue and maternal blood samples were collected from 
Caucasian women at the First Department of Obstetrics and 
Gynaecology, Semmelweis University in Budapest, Hungary 
as described previously (132). Pregnancies were dated accord-
ing to ultrasound scans between 8 and 12  weeks of gestation. 
Patients with multiple pregnancies or fetuses having congenital 
or chromosomal abnormalities were excluded. The collection 
and investigation of human clinical samples were approved by 
the Health Science Board of Hungary. Written informed consent 
was obtained from women prior to sample collection, and the 
experiments conformed to the principles set out in the World 
Medical Association Declaration of Helsinki and the Department 
of Health and Human Services Belmont Report. Specimens and 
data were stored anonymously.
Women were enrolled in the following groups: (1) preterm 
severe preeclampsia, with or without HELLP (hemolysis, elevated 
liver enzymes, low platelets) syndrome (n = 12) and (2) preterm 
controls (n = 5) (Table 1). Preeclampsia was defined according 
to the criteria set by the American College of Obstetricians and 
Gynecologists (1), and subdivided into preterm (<37  weeks) 
or term (≥37  weeks) groups. Severe preeclampsia was defined 
according to Sibai et  al. (2). Preterm controls had no medical 
complications, clinical or histological signs of chorioamnionitis, 
and delivered neonates with a BW appropriate-for-gestational age 
(AGA) (312). SGA was defined as neonatal BW below the 10th 
percentile for gestational age. Cesarean delivery was performed 
in all cases due to severe symptoms as well as in all controls due 
to previous Cesarean delivery or malpresentation.
Placental Tissue and Maternal Blood Collection
Placental tissue specimens were processed immediately after 
delivery as described previously (132). For the microarray 
study, 1 × 1 cm villous tissue samples were excised from central 
cotyledons close to the umbilical cord to reduce the possible bias 
due to regional differences in gene expression (313, 314). These 
tissue blocks were then dissected from the choriodecidua on 
dry ice, snap-frozen, and stored at −80oC. For histopathologic 
evaluations, five representative tissue blocks were taken from 
each placenta to include central and peripheral cotyledons and 
the maternal side of the placenta with the fetal membranes. 
These blocks were embedded in paraffin after fixation in 10% 
neutral-buffered formalin (FFPE). Maternal blood samples were 
obtained at the time of admission into the delivery room; aliquots 
of maternal sera and plasma were stored at −80oC.
Histopathologic Evaluation of the Placentas
Placental specimens were examined according to a standard pro-
tocol, describing the topography and size of macroscopic lesions. 
Four micrometer sections were cut from the five FFPE blocks 
and mounted on SuperFrost/Plus slides (Fisherbrand, UK). After 
deparaffinization, slides were rehydrated, stained with hematoxy-
lin and eosin, and examined in 10 randomly chosen microscopic 
fields using bright-field light microscopy by a pathologist blinded 
to the clinical information. Macroscopic and microscopic lesions 
were defined according to published criteria (315–317).
Placental Total RNA Isolation and Microarray Experiments
Tissues were homogenized using a ThermoSavant FastPrep FP120 
Homogenizer (Thermo Scientific, Wilmington, DE, USA) with 
Lysing MatrixD (MP Biomedicals, Illkirch, France). Total RNA 
was isolated using RNeasy Fibrous Tissue Mini Kit (QIAGEN 
GmbH, Hilden, Germany), quantified with NanoDrop 1000 
(Thermo Scientific), and assessed by Agilent 2100 Bioanalyzer 
(Matriks AS, Oslo, Norway). Total RNAs were labeled, and Cy3-
RNAs were fragmented and hybridized to the Whole Human 
Genome Oligo Microarray G4112A (Agilent Technologies, 
Santa Clara, CA, USA) on an Agilent scanner, and processed 
with Agilent Feature Extraction software v9.5 according to the 
manufacturer’s guidelines.
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Data Analysis
Demographics data were compared by the Fisher’s exact test 
and Mann–Whitney test using SPSS version 12.0 (SPSS Inc., 
Chicago, IL, USA). Microarray data analysis was performed 
using the R statistical language and environment1 following the 
MIAME guidelines and methodologies described previously 
(318). Microarray expression intensities were background cor-
rected using the “minimum” method in the “backgroundCorrect” 
function of the “limma” package (319). After log2 transforma-
tion, data were quantile-normalized. From the 41,093 probesets 
on the array, 93 were removed before differential expression 
analysis, lacking annotation in the array definition file (Agilent 
Technologies). Subsequently, an expression filter was applied to 
retain probesets with intensity greater than log2(50) in at least two 
samples, yielding a final matrix of 30,027 probesets (15,939 unique 
genes). Differential gene expression was assessed using linear 
models including adjustment for batch effects, with coefficient 
evaluation via moderated t-tests. P-values were adjusted using 
the false discovery rate (FDR) method and Benjamini–Hochberg 
correction to compute q-values. Since there were no differences 
among patient groups in maternal age or ethnic background, we 
did not adjust for these parameters. Target gene Entrez IDs for 
the probesets were determined using the R package “hgu4112a.
db.” For probesets without annotation in the package, Entrez IDs 
were taken from the array definition file (Agilent Technologies). 
Probesets remaining un-annotated (without Entrez ID and/or 
gene symbol) were removed from further analysis. Probesets were 
defined as DE (n = 1,409) if they had a q ≤ 0.2 and a fold-change 
≥1.5 (Data S1 in Supplementary Material).
From the DE genes in preeclampsia, those encoding for pro-
teins with functions in transcription regulation (n = 137) were 
identified using the Metacore (GeneGo Inc., Saint Joseph, MI, 
USA) and GeneCards v32 databases.
We downloaded the human U133A/GNF1H microarray data 
on 79 human tissues, cells, and cell lines from the Symatlas/
BioGPS database (151) to identify human genes with pre-
dominant placental expression. A probeset was defined as having 
predominant placental expression if its placental expression 
was (1) ≥1,000 fluorescence units; (2) six times higher than the 
median value in 78 other tissue and cell sources; and (3) two times 
higher than its expression in the tissue with the second highest 
expression. The resulting 215 probesets corresponded to 153 
unique genes. Eleven additional genes that were not present on 
the microarray platform used by Symatlas/BioGPS (Affymetrix, 
Santa Clara, CA, USA) were added to this list based on previously 
published evidence of placenta-specific expression (151–153) 
(Data S2 in Supplementary Material). Of the 164 predominantly 
placenta-expressed genes, 157 were present in our placental 
microarray data. These genes were tested for enrichment in DE 
genes compared to all genes on the array (1,409 of 15,939) using 
the Fisher’s exact test.
The expression levels of DE genes in EVT compared to VT lin-
eages were analyzed by retrieving published microarray datasets 
1 www.r-project.org.
2 www.genecards.org.
(320–322) and reanalyzing expression data. Raw Affymetrix 
GeneChip Human Genome U133A 2.0 Array data from Bilban 
et al. (320) and Tilburgs et al. (322) was downloaded from GEO 
(GSE9773) and ArrayExpress (E-MATB-3217) respectively, and 
was processed with the “affy” (323) and “limma” (324) packages of 
Bioconductor.3 After RMA normalization, log-fold changes were 
calculated. Processed Illumina Human HT-12 V3 BeadArray 
data from Apps et al. (321) was downloaded from ArrayExpress 
(E-MATB-429), and then log-fold changes were calculated.
Chromosomal locations for all genes tested on the Agilent 
array were obtained from the R package “org.Hs.eg.db.” Of the 
15,939 unique and 1,409 DE genes on the array, 15,935 and 
1,408 could be assigned to chromosomes, respectively. Mapping 
the microarray probesets on the Affymetrix human U133A/
GNF1H chips to ENTREZ identifiers was performed using the 
Bioconductor “hgu133a.db” and “hgfocus.db” packages (325, 
326). Chromosomal locations of the resulting list of genes were 
obtained from the package “org.Hs.eg.db” and from the National 
Center for Biotechnology Information for the 11 additional genes 
(327). Enrichment analyses for chromosomes among predomi-
nantly placenta-expressed genes, DE genes and DE genes encod-
ing for transcriptional regulators (Data S3–S5 in Supplementary 
Material) were tested by the Fisher’s exact test. Chromosomal 
locations of these genes were visualized by Circos (328).
Weighted gene co-expression network analysis (329, 330) was 
applied on the 1,409 DE genes across 17 samples to identify distinct 
regulatory modules and prioritize candidate genes for qRT-PCR 
validation. A gene pair-wise similarity (absolute Pearson correla-
tion) matrix was first computed, then soft-thresholded by raising 
it to the power of 10 (chosen based on the scale-free topology 
criterion) to obtain an adjacency matrix. The topology overlap 
matrix (TOM) was then derived from the adjacency matrix. The 
topology overlap (331) measures the node interconnectedness 
within a network and was generalized to WGCNA (329). This 
measure defines the similarity between the two genes based on 
both correlations within themselves and outside other genes. 
Gene distance matrix was defined as 1-TOM and used for average 
linkage hierarchical clustering. A hybrid dynamic tree-cutting 
method (332) was applied to obtain modules (tree clusters).
Gene modules identified with this approach were further 
tested for enrichment in DE genes using the Fisher’s exact test. 
Transcription regulatory genes expressed at high levels (average 
log2 intensity >9) and co-expressed (absolute Pearson coefficient 
>0.7) with the most genes among DE genes were treated as candi-
dates for hub genes in the module. Hub genes then were selected 
based on the number and strength of their Pearson co-expression 
partners as well as their and their networks’ biological activities. 
The networks of biological processes enriched among genes co-
expressed with hub factors modules were created by BINGO and 
visualized with Cytoscape.
Enrichment analysis of transposable elements present in the 
10,000 bp upstream region of DE genes was performed separately 
for the M1 (green) and the M2 (red) modules in preeclampsia 
versus all genes present on the microarray using the Fisher’s exact 
3 www.bioconductor.org.
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test. The locations of transposable elements and their families and 
classes were obtained from the “RepeatMasker” table of the UCSC 
Table Browser.4 P-values <0.05 were considered significant.
Placental Validation Study
Study Groups and Clinical Definitions
Third trimester placentas (n  =  100) collected predominantly 
from African-American women were retrieved from the Bank 
of Biological Specimens of the Perinatology Research Branch 
(Detroit, MI, USA). Pregnancies were dated according to 
ultrasound scans between 8 and 12  weeks. Patients with mul-
tiple pregnancies or fetuses having congenital or chromosomal 
abnormalities were excluded. The use of biological specimens 
and clinical data for research purposes was approved by the 
Wayne State University Human Investigation Committee and 
the Institutional Review Board of the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development 
(NICHD, NIH, DHHS). Written informed consent was obtained 
from women prior to sample collection, and the experiments 
conformed to the principles set out in the World Medical 
Association Declaration of Helsinki and the Department of 
Health and Human Services Belmont Report. Specimens and 
data were stored anonymously.
The following homogenous patient groups were selected from 
a cohort: (1) preterm severe preeclampsia (n = 20); (2) preterm 
severe preeclampsia associated with SGA (n = 20); (3) preterm 
controls (n = 20); (4) term severe preeclampsia (n = 10); (5) term 
severe preeclampsia associated with SGA (n = 10); and (6) term 
controls (n = 20). Term controls, consisting of normal pregnant 
women with (n =  10) or without (n =  10) labor, and preterm 
controls with preterm labor and delivery had no medical com-
plications or clinical or histological signs of chorioamnionitis, 
and delivered an AGA neonate (333) (Table  2; Figure S2 in 
Supplementary Material).
Labor was defined by the presence of regular uterine contrac-
tions at a frequency of at least two contractions every 10  min 
with cervical changes resulting in delivery (334). Preeclampsia 
was defined according to the criteria set by the American College 
of Obstetricians and Gynecologists (1) and was subdivided 
into preterm (<37 weeks) or term (≥37 weeks) groups. Severe 
preeclampsia was defined according to Sibai et al. (2). SGA was 
defined as neonatal BW below the 10th percentile for gestational 
age (333). Cesarean delivery was performed in cases due to severe 
symptoms and in controls due to previous Cesarean delivery or 
malpresentation.
Placental Tissue Collection
Third trimester placental tissue specimens (n  =  100) were 
processed immediately after delivery. For histopathologic evalu-
ations, representative tissue blocks were taken from each placenta 
to include central and peripheral cotyledons, maternal side of the 
placenta, fetal membranes, and the umbilical cord. These blocks 
were embedded in paraffin after fixation in 10% neutral-buffered 
formalin (FFPE). Villous tissue blocks from central cotyledons 
4 http://genome.ucsc.edu/.
were selected for TMA. For gene expression studies, systematic 
random sampling (335) was used to obtain villous tissues to 
reduce the possible bias due to regional gene expression differ-
ences (313, 314). Excised tissue blocks were homogenized and 
mixed in TRIzol reagent (Life Technologies), snap-frozen with 
liquid N2, and stored at −80oC.
Histopathologic Evaluation of the Placentas
Placental specimens (n = 100) were examined according to a stand-
ard protocol, describing the topography and size of macroscopic 
lesions. Five µm sections were cut from the representative FFPE 
tissue blocks, stained with hematoxylin and eosin, and examined 
using bright-field light microscopy by two anatomic pathologists 
blinded to the clinical information. Histopathologic changes of the 
placenta were defined according to published criteria proposed by 
the Perinatal Section of the Society for Pediatric Pathology (336). 
“Maternal vascular malperfusion score” was calculated by sum-
ming the number of pathologic lesions consistent with this lesion 
category (46, 336) present in a given placenta.
Placental Total RNA Isolation and qRT-PCR
Total RNA was isolated from snap-frozen third trimester 
placental villous tissues (n  =  100) with TRIzol reagent (Life 
Technologies) and RNeasy kit (QIAGEN, Valencia, CA, USA) 
according to the manufacturers’ recommendations. The 28S/18S 
ratios and the RNA integrity numbers were assessed using an 
Agilent Bioanalyzer 2100, and RNA concentrations were meas-
ured with NanoDrop 1000. Total RNA (500 ng) was reverse tran-
scribed with the High Capacity cDNA Reverse Transcription Kit 
using random hexamers (Applied Biosystems, Foster City, CA, 
USA). TaqMan Assays (Applied Biosystems; Table 3, Data S17 
in Supplementary Material) were used for high-throughput gene 
expression profiling on the Biomark qRT-PCR system (Fluidigm, 
San Francisco, CA, USA) according to the manufacturers’ 
instructions.
Placental TMA Construction, Immunohistochemistry, and 
Immunoscoring
Tissue microarrays were constructed from central tissue blocks 
of third trimester FFPE placentas (n = 100) as described earlier 
(337). Briefly, three 20 ×  35  mm recipient blocks were made 
of Paraplast X-Tra tissue embedding media (Fisher Scientific, 
Pittsburgh, PA, USA). One mm diameter cores from tissue blocks 
were transferred in triplicate into recipient paraffin blocks using 
an automated tissue arrayer (Beecher Instruments, Inc., Silver 
Spring, MD, USA). Five µm sections cut from TMAs were placed 
on silanized slides and stained with antibodies and reagents (Data 
S18 in Supplementary Material) either on Ventana Discovery or 
Leica BOND-MAX autostainers.
Tissue microarray immunostainings were semi-quantitatively 
scored by three examiners blinded to the clinical information 
with an immunoreactive score modified from a previously 
published one (154). Immunostaining intensity was graded as 
follows: 0 = negative, 1 = weak, 2 = intermediate, and 3 = strong. 
All villi in a random field of each of the three cores were evalu-
ated by all examiners, and scores within each core were averaged 
to represent the target protein quantity of that core. Thus, each 
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placenta had three scores corresponding to the three cores 
examined.
Data Analysis
Demographics data were compared by the Fisher’s exact test and 
Mann–Whitney test using SPSS version 12.0 (SPSS). All other data 
were analyzed in the R statistical environment (see text footnote 1).
Placental qRT-PCR. Data were analyzed using the ΔΔCt 
method. Data were first normalized to the reference gene 
(RPLP0), and the batch effect was adjusted through calibrator 
samples. Log2 mRNA relative concentrations were obtained for 
each sample as −ΔCt(gene) = Ct(RPLPO) − Ct(gene). The surrogate gene 
expression values (−ΔCtgene) were used to perform a hierarchi-
cal clustering with 1-Pearson correlation distance and average 
linkage. Between-group comparisons (in which groups were pre-
defined based on the clinical characteristics of the patients) were 
performed by fitting a linear model on −ΔCt values, using the 
group variable indicator and the maturity status of the fetus (term 
vs. preterm) as covariates while allowing for an interaction effect 
(Figure 4; Figure S3 in Supplementary Material).
Histopathology. The association between qRT-PCR gene 
expression and the “maternal vascular malperfusion” score was 
tested using a linear model. P-values of <0.05 were considered 
significant.
TMA Immunoscoring. Group comparisons using immuno-
scores were conducted in the same way as for the qRT-PCR data 
(Figure 4).
Correlation of Clinical Parameters and Placental 
Gene Expression
Data Analysis
To reveal whether the expression of any gene on the microar-
ray was correlated with MAP while controlling for BW, a linear 
model (y~MAP +  BW +  Batch) was fit for every gene on the 
array, in which y represents gene expression, and the dependent 
variables represent MAP, BW, and batch, respectively. A moder-
ated t-test was used to obtain p-values, which then were adjusted 
using the FDR method and Benjamini–Hochberg correction for 
multiple testing. Significance was determined using a q ≤  0.2. 
Gene modules were also tested for the enrichment in genes with 
their expression correlated with MAP using the Fisher’s exact test 
(Data S6 in Supplementary Material).
In the qRT-PCR validation study, we extended our analysis to 
include all 100 patients to test for the association between gene 
expression and mean arterial BP as well as BW percentile while 
adjusting for gestational age. All variables were treated as con-
tinuous. P-values of <0.05 were considered significant (Figure 4).
Genomic DNA Methylation Analysis of the 
Trophoblast
Laser Capture Microdissection
Fifteen µm sections were cut from snap-frozen placentas that were 
also used for qRT-PCR expression profiling (n = 100) on 2 µm 
Glass Foiled PEN slides (Leica Microsystems). The trophoblast 
layer of 300–350 villi in each specimen was laser captured by a 
Leica DM6000B microscope (Leica Microsystems) into 0.5  ml 
microcentrifuge tubes. The captured material was digested with 
Proteinase K (PicoPure DNA Extraction Kit, Applied Biosystems) 
at 56°C by overnight incubation. Digestions were stopped at 95°C, 
and samples were stored at −70°C until DNA isolation.
Genomic DNA Isolation
Genomic DNA was isolated from laser captured VTs (n = 100), 
from primary VTs (n  =  3) collected for functional studies 
described below, and from respective umbilical cord blood 
leukocytes (n =  3) taken from the same pregnancies. The EZ1 
Advanced Nucleic Acid Isolation System using EZ1 DNA Tissue 
and EZ1 DNA Blood Kits (QIAGEN) were utilized for DNA isola-
tion, and DNA samples were quantified with Quantifiler Human 
DNA Quantification Kit (Applied Biosystems) according to the 
manufacturers’ instructions.
Primer Design and Validation
The methylation status of CpGs in human H1 embryonic stem 
cells, H1-derived trophoblast cultured cells, and H1-derived 
neuronal progenitor cultured cells obtained by whole-genome 
shotgun bisulfite sequencing (University of California, San 
Diego, USA; UCSD Human Reference Epigenome Mapping 
Project) were visualized by the Epigenome Browser5 and 
used for the selection of regions of interest. Primer design, 
targeted amplification, and sequencing were conducted using 
the targeted sequencing service protocol of Zymo Research 
Corporation. For targeted bisulfite sequencing, 30 primer pairs 
were designed and validated. Primers were synthesized by 
Integrated DNA Technologies, Inc., (Coralville, IA, USA) and 
underwent quality control, which included duplicate testing 
for specific amplification of 1 ng bisulfite DNA using bisulfite 
converted human DNA. Quality control criteria included 
robust and specific amplification (Cp values <40 cycles and CV 
<10% for duplicates) of the bisulfite primers on a LightCycler 
480 real-time qRT-PCR instrument (Roche Diagnostics Corp. 
Indianapolis, IN, USA).
Bisulfite Conversion, Multiplex Amplification, Bar-Coding 
and Adapterization PCR, and Next-Generation Sequencing
Genomic DNA samples from laser captured VTs, primary VTs, 
and umbilical cord blood cells as well as control samples were 
subjected to sodium bisulfite treatment using the EZ DNA 
Methylation-Direct Kit (Zymo Research Corporation). For non-
methylated control, human DNA was extracted and purified 
with Quick-gDNA Miniprep Kit (Zymo Research Corporation) 
from the HCT116 cell line (American Type Culture Collection, 
Manassas, VA, USA), which is double knock-out for both DNA 
methyltransferases DNMT1 (−/−) and DNMT3b (−/−), and thus 
contains a low level (<5%) of DNA methylation. For methylated 
control, human DNA was purified similarly from the HCT116 
cell line and was enzymatically methylated at all cytosine posi-




Than et al. Preclinical Pathways of Preeclampsia
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1661
Bisulfite-treated samples and 30 validated primer pairs were 
subjected to targeted amplification on the 48.48 Access Array 
System (Fluidigm), using the targeted sequencing service 
protocol of Zymo Research Corporation. Fluidigm’s protocols 
were used for sample loading, harvesting, and pooling, 1:100 
dilution of amplicon pools for each sample, and for amplifica-
tion using barcoded adapter-linkers (Fluidigm). Reactions were 
cleaned up using the DNA Clean and Concentrator-5 (Zymo 
Research Corporation), and products were normalized by con-
centration and pooled. The sequencing library was denatured, 
diluted, and sequenced with a 150-base paired-end run on the 
MiSeq Benchtop Sequencer (Illumina) according to Illumina’s 
protocols.
Sequence Alignment and Data Analysis
Sequence reads from bisulfite-treated libraries were identified 
using standard Illumina base-calling software, and then analyzed 
using a Zymo Research Corporation proprietary analysis pipe-
line. Residual cytosines (Cs) in each read were first converted 
to thymines (Ts), with each such conversion noted for subse-
quent analysis. Reads were aligned by Bismark, a Bowtie-based 
alignment tool for bisulfite converted reads.6 The number of 
mismatches in the induced alignment was then counted between 
the unconverted read and reference, ignoring cases in which a T 
in the unconverted read was matched to a C in the unconverted 
reference. For a given read, only the best scored alignment was 
kept. If there were more than one best read, then only one was 
kept arbitrarily. The methylation level of each sampled cytosine 
was estimated as the number of reads reporting a C, divided by 
the total number of reads reporting a C or T. CpGs with cover-
age of less than four reads were removed from the analysis. The 
developed sensitive and robust bisulfite sequencing assays yielded 
a median total sequencing read of 533 (range: 30–1,725) per CpG 
in the trophoblast-fetal blood cell comparison and a median total 
sequencing read of 136 (range: 4–2,609) per CpG in the clinical 
sample comparison.
Multiple sequencing counts (total and methylated) were 
summed for each sample at each CpG site, and samples with 
a total count <4 were dropped from the analysis. The mean 
methylation ratio in each group was computed for genomic 
visualization. In the comparison of methylation levels between 
trophoblasts and cord blood cells, a group sample size of two 
was considered as a minimum. In order to fit the count data, we 
used a generalized linear model of Poisson distribution with log 
link. When all samples in any of the two groups being compared 
had zero methylation counts, the maximum likelihood estima-
tion of the Poisson model went to infinity. In such cases, the 
Student’s t-test was used alternatively. P-values and the group 
difference in methylation ratios were included above the bar 
plots in Figures S9 and S12 in the Supplementary Material. For 
comparisons of methylation levels between the clinical groups, 
only comparisons with a minimum group sample size of four 
were considered, and the Wilcoxon rank-sum test was used. 
P-values and the group difference in methylation ratios were 
6 http://www.bioinformatics.babraham.ac.uk/projects/download.html#bismark.
included above the bar plots in Figure 11 as well as Figures S10 
and S13 in the Supplementary Material. Differential methyla-
tion was considered to be mild, moderate, or strong when the 
p-value was <0.05 and the difference in methylation ratios was 
≥0.125, ≥0.25, or ≥0.5, respectively. The correlation between 
methylation levels on each CpG in clinical samples and various 
demographical, clinical, or histopathological variables were 
evaluated by Kendall’s tau statistics. Correlation coefficients and 
p-values were plotted in the scatter plots. A Kendall’s tau p < 0.05 
was considered significant.
Maternal study
“Virtual” Liquid Biopsy of the Placenta in Preterm 
Preeclampsia
Sample Collection
First trimester placentas and maternal blood samples were col-
lected from healthy Caucasian women undergoing termination 
of pregnancy (n = 12), and processed at the Maternity Clinic and 
Semmelweis University in Budapest, Hungary. Villous tissues 
were dissected from the choriodecidua on dry ice and stored 
at −80oC. Aliquots of maternal sera and plasma were stored at 
−80oC.
Pregnancies were dated according to ultrasound scans 
between 5 and 13  weeks of gestation. Patients with multiple 
pregnancies were excluded. The collection and investigation of 
human clinical samples were approved by the Health Science 
Board of Hungary. Written informed consent was obtained 
from women prior to sample collection, and the experiments 
conformed to the principles set out in the World Medical 
Association Declaration of Helsinki and the Department of 
Health and Human Services Belmont Report. Specimens and 
data were stored anonymously.
Placental Total RNA Isolation and qRT-PCR
Total RNA was isolated from snap-frozen first trimester placental 
villous tissues (n = 12) with Direct-zol RNA MiniPrep Kit (Zymo 
Research Corporation) according to the manufacturer’s recom-
mendations. The 28S/18S ratios and the RNA integrity numbers 
were assessed using an Agilent Bioanalyzer 2100 (Agilent 
Technologies), and RNA concentrations were measured with 
NanoDrop 1000. Total RNA (500  ng) was reverse transcribed 
with the qScript cDNA Synthesis Kit (Quanta Biosciences, 
Gaithersburg, MD, USA). TaqMan Assays (Applied Biosystems; 
Data S17 in Supplementary Material) were used for expression 
profiling on the StepOnePlus Real-Time PCR System (Applied 
Biosystems).
Enzyme-Linked Immunosorbent Assays
Concentrations of leptin and human placental lactogen (hPL) 
in first (n =  12) and third (n =  19) trimester maternal blood 
samples were measured with sensitive and specific immunoas-
says (Leptin ELISA Kit, Abnova, Taipei City, Taiwan; Human 
Placental Lactogen ELISA Kit, Alpco, Salem, NH, USA) 
according to the manufacturers’ instructions. Standard curves 
were generated, and sample assay values were extrapolated. The 
sensitivities of the assays were <4.4 ng/ml (leptin) and <550 ng/
ml (hPL).
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Correlation Analysis of Placental Gene Expressions and 
Maternal Plasma Protein Concentrations
Placental gene expression was measured with either microarray 
on third trimester samples or qRT-PCR on first trimester samples 
as described above. Maternal plasma protein concentrations were 
measured with the above-described immunoassays on respective 
blood samples taken from the same patients on the day of either 
delivery or termination of pregnancy. Correlations between pla-
cental gene expression and maternal plasma concentrations of gene 
product proteins were calculated with the Pearson method and 
visualized on scatter plots (Figure S4 in Supplementary Material).
Publication Search, Database Build, and “Virtual” Liquid 
Biopsy of the Placenta
To detect disease-associated protein signatures of placental 
dysfunction in maternal blood, similar to plasma DNA tissue 
mapping for noninvasive prenatal, cancer, and transplantation 
assessments (176), we performed “virtual” liquid biopsy of the 
placenta. Briefly, human microarray data on 79 human tissues 
and cells were downloaded from the BioGPS database, which was 
used for the generation of placenta enrichment scores (placental 
expression/mean expression in 78 other tissues and cells). Five 
genes (CGB3, CSH1, ENG, FLT1, and LEP) with enrichment 
scores between 1.4 and 1,490 were selected based on a literature 
search due to the extensive investigations of their gene products 
in maternal blood in preeclampsia (Figure S5 in Supplementary 
Material). Next, an extensive PubMed search was conducted for 
first trimester maternal blood protein measurements of these five 
gene products in patients who developed preeclampsia later in 
pregnancy. Altogether, 61 scientific reports were identified that 
met the inclusion criteria, which contained data for 80,170 meas-
urements (35, 61, 82, 88, 126, 178–233). These reports were used 
to build a database for the “virtual” liquid biopsy. In this database, 
biomarker levels in preterm preeclampsia were expressed as the 
percentage of control levels as a function of gestational age. Then, 
the correlations of control percentage values with gestational age 
were evaluated using the Pearson method. Scatterplots were used 
to visualize data (Figure S5 in Supplementary Material; Figure 5).
Maternal Serum Proteomics Discovery Study
Study Groups, Clinical Definitions, and Sample Collection
Women were enrolled in a prospective, longitudinal, and multi-
center study (196) in prenatal community clinics of the Maccabi 
Healthcare Services, Israel. Pregnancies were dated according to 
the last menstrual period and verified by first trimester ultrasound. 
Patients with multiple pregnancies or fetuses having congenital or 
chromosomal abnormalities were excluded. The collection and 
investigation of human clinical samples were approved by the 
Maccabi Institutional Review Board. Written informed consent 
was obtained from women prior to sample collection, and the 
experiments conformed to the principles set out in the World 
Medical Association Declaration of Helsinki and the Department 
of Health and Human Services Belmont Report. Specimens and 
data were stored anonymously.
Preeclampsia was defined according to the criteria set by 
the International Society for the Study of Hypertension in 
Pregnancy (338) and was subdivided into preterm (<37 weeks) 
or term (≥37 weeks) groups. Severe preeclampsia was defined by 
Sibai et al. (2). SGA was defined as neonatal BW below the 10th 
percentile for gestational age. Healthy controls had no medical 
or obstetric complications and delivered a neonate with a BW 
appropriate for gestational age.
Peripheral blood samples were obtained by venipuncture in the 
first trimester from women who subsequently developed preterm 
severe preeclampsia (n = 5) and term severe preeclampsia (n = 5) 
as well as healthy controls (n =  10) matched for gestational age 
at blood draw (Table 4). Blood samples were allowed to clot and 
were then centrifuged at 10,000 ×  g for 10  min to separate and 
collect sera. Serum samples were stored in aliquots at −20oC in the 
Maccabi Central Laboratory until shipped on dry ice to Hungary.
Sample Preparations, Immunodepletion of High-Abundance 
Serum Proteins
Sera were immunodepleted at Biosystems International Ltd., 
(Debrecen, Hungary) for 14 highly abundant serum proteins on 
an Agilent 1100 HPLC system using Multiple Affinity Removal 
LC Column-Human 14 (Agilent Technologies) according to the 
manufacturer’s protocol. To improve the resolution of 2D gels, 
immunodepleted serum samples were lyophilized, delipidated, 
and salt-depleted at the Proteomics Laboratory of the Eotvos 
Lorand University (Budapest, Hungary) (339). The delipidated 
and salt-depleted plasma protein samples were dissolved in lysis 
buffer, and their pH was adjusted to 8.0.
Fluorescent Labeling and 2D-DIGE
Protein concentrations of the immunodepleted, desalted, 
and delipidated serum samples were between 2 and 4  µg/µl as 
determined with PlusOne 2D Quant Kit (GE Healthcare, Little 
Chalfont, United Kingdom). Samples were equalized for protein 
content, and then 5 µg of each protein sample was labeled with 
a CyDye DIGE Fluor Labeling kit for Scarce Samples (saturation 
dye) (GE Healthcare) according to the manufacturer’s instruc-
tions. Individual samples from cases (n =  2 ×  5) and controls 
(n = 2 × 5) were labeled with Cy5. An internal standard reference 
sample was pooled from equal amounts (2.5 µg) of all individual 
samples in this experimental set and was labeled with Cy3. Then, 
5 µg of each Cy5-labeled individual sample was merged with 5 µg 
of the Cy3-labeled reference sample, and these 20 mixtures were 
run in 2 × 10 gels simultaneously. Briefly, labeled proteins were 
dissolved in isoelectric focusing (IEF) buffer and were rehydrated 
passively onto 24 cm immobilized non-linear pH gradient (IPG) 
strips (pH 3–10, GE Healthcare) for at least 14 h at room tem-
perature. After rehydration, the IPG strips were subjected to the 
first dimension of IEF for 24 h to attain a total of 80 kVh. Focused 
proteins were reduced by equilibrating with a buffer containing 
1% mercaptoethanol for 20 min. After reduction, IPG strips were 
loaded onto 10% polyacrylamide gels (24 ×  20  cm) and SDS-
PAGE was conducted at 12W/gel in the second dimension. Then, 
gels were scanned in a Typhoon TRIO + scanner (GE Healthcare) 
using appropriate lasers and filters with the photomultiplier tube 
biased at 600V. Images in different channels were overlaid using 
selected colors, and the differences were visualized using Image 
Quant software (GE Healthcare). Differential protein expression 
analysis was performed using the differential in-gel analysis and 
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biological variance analysis (BVA) modules of the DeCyder 6.0 
software package (GE Healthcare).
Identification of DE Protein Spots
The internal standard reference sample representative of every 
protein present in all experiments was loaded equally in all gels 
and thus provided an average image for the normalization of 
individual samples. The determination of the relative abundance 
of the fluorescent signal between internal standards across all 
gels provided standardization between the gels, removing experi-
mental variations and reducing gel-to-gel variations. According 
to the standard proteomic protocol, the threshold for differential 
expression was set at 1.05-fold minimum fold-change (340). A 
p-value was determined for each protein spot using the Student’s 
t-test by the BVA module of the DeCyder software. A p-value of 
<0.05 was considered statistically significant.
Sample Preparation, Fluorescent Labeling, and Preparative 
2D-DIGE
The density of spots in the case of Colloidal Coomassie Blue 
labeling depends only on the concentration of protein in the 
sample; however, the density of the spots in the case of satura-
tion dye labeling also depends on the number of cysteines of 
the labeled proteins because the saturation dye labeling method 
labels all available cysteines on each protein. This results in 
the same pattern with different density among samples on the 
analytical and the preparative gels, rendering identification more 
difficult. To eliminate this problem for the exact identification of 
proteins in spots of interest, preparative 2D gel electrophoresis 
was performed using CyDye saturation fluorescent labeling and 
Colloidal Coomassie Blue labeling in the same gel. A total of 
800 µg of proteins per each of the two gels was run. Following 
electrophoresis, gels were scanned in a Typhoon TRIO + scanner 
as described above, the significantly altered spots were matched 
among the “master” analytical and the fluorescent preparative gel 
images using the BVA module of the DeCyder 6.0 software pack-
age. The resolved protein spots were visualized by the Colloidal 
Coomassie Blue G-250 staining protocol. Individual spots of 
interest were excised from the gels based on the comparison of 
the matched images.
In-Gel Digestion, Liquid Chromatography–Tandem Mass 
Spectrometry (LC–MS/MS)
The excised protein spots were analyzed at the Proteomics 
Research Group of the Biological Research Center of the 
Hungarian Academy of Sciences (Szeged, Hungary); the detailed 
protocol is described in http://ms-facility.ucsf.edu/ingel.html. 
Briefly, salts, SDS, and Coomassie brilliant blue dye were washed 
out, disulfide bridges were reduced with dithiothreitol, and then 
free sulfhydryls were alkylated with iodoacetamide. Digestion 
with side-chain protected porcine trypsin (Promega, Madison, 
WI, USA) proceeded at 37°C for 4 h. The resulting peptides were 
extracted from the gel using 1% formic acid in 50% acetonitrile; 
then the samples were dried down and dissolved in 0.1% formic 
acid.
Samples were analyzed on an Eldex nanoHPLC system online 
coupled to a 3D ion trap tandem mass spectrometer (LCQ Fleet, 
Thermo Scientific) in “triple play” data-dependent acquisition 
mode, where MS acquisitions were followed by CID analyses 
on computer-selected multiply charged ions. HPLC conditions 
included in-line trapping onto a nanoACQUITY UPLC trapping 
column (Symmetry, C18 5  µm, 180  µm ×  20  mm; and 15  µl/
min with 3% solvent B) followed by a linear gradient of solvent 
B (5–60% in 35  min, flow rate: 300  nl/min, where solvent A 
was 0.1% formic acid in water and solvent B was 0.1% formic 
acid in acetonitrile) on a Waters Atlantis C18 Column (3  µm, 
75 µm × 100 mm).
Database Search and Data Interpretation
Raw data files were converted into Mascot generic files (*.mgf) 
with the Mascot Distiller software v2.1.1.0 (Matrix Science Inc, 
London, UK). The resulting peak lists were searched against a 
human subdatabase of the non-redundant protein database of the 
NCBI (NCBInr, Bethesda, MD, USA) in MS/MS ion search mode 
on an in-house Mascot server v2.2.04 using Mascot Daemon 
software v2.2.2 (Matrix Science Inc). Monoisotopic masses with 
peptide mass tolerance of ±0.6  Da and fragment mass toler-
ance of ±1 Da were submitted. Trypsin with up to two missed 
cleavages was specified as an enzyme. Carbamidomethylation of 
cysteines was set as fixed modification, and acetylation of protein 
N-termini, methionine oxidation, and pyroglutamic acid forma-
tion from peptide N-terminal glutamine residues were permitted 
as variable modifications. Acceptance criterion was set to at least 
two significant (peptide score >40, p < 0.05) individual peptides 
per protein. Localization of identified peptides in the core protein 
sequences was visually analyzed in order to identify potential 
protein split products.
Biological functions of the altered serum proteins were 
retrieved from Pathway Studio 9.0 software (Ariadne Genomics 
Inc., Rockville, MD, USA), and from the open-access GO database7 
(Figure 6; Figure S6 and Data S8 in Supplementary Material). To 
elucidate possible interactions between the altered serum proteins 
and placental genes in the microarray data, bioinformatics analy-
sis was performed using the same software. Molecular networks 
between the changed serum proteins in preterm (n = 19) or term 
preeclampsia (n = 14) and DE placental genes annotated in the 
GO database (n = 1,142) were built separately with a non-linear 
literature processing search engine, and the resulting connec-
tions were manually validated by reading full-text publications 
(Figure  6; Figure S6 in Supplementary Material). The Fisher’s 
exact test was used to test for the enrichment of the connections 
between the altered serum proteins and (1) DE genes in indi-
vidual modules, taking the connections between the proteins and 
DE genes in all modules as a background; and (2) DE placental 
genes, taking the connections between the proteins and all genes 
tested on the array as a background. To reveal the pathways 
enriched among the DE genes connected to angiotensinogen, the 
Ingenuity Pathway Analysis software (QIAGEN, Redwood City, 
Redwood City, CA, USA) was used, which utilizes Fisher’s exact 
test and Benjamini–Hochberg correction for multiple testing for 
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Maternal Serum Proteomics Validation Pilot Study
Study Groups, Clinical Definitions, and Sample Collection
Caucasian women were enrolled in a prospective study at the 
Department of Obstetrics and Gynaecology of the University 
of Debrecen and at the Andras Josa Teaching Hospital in 
Nyiregyhaza, Hungary. Pregnancies were dated according to 
ultrasound scans between 8 and 14 weeks of gestation. Patients 
with multiple pregnancies or fetuses having congenital or 
chromosomal abnormalities were excluded. The collection and 
investigation of human clinical samples were approved by the 
Regional Ethics Committee of the University of Debrecen. Written 
informed consent was obtained from women prior to sample col-
lection, and the experiments conformed to the principles set out 
in the World Medical Association Declaration of Helsinki and 
the Department of Health and Human Services Belmont Report. 
Specimens and data were stored anonymously.
Women were included in the following groups: (1) preterm 
severe preeclampsia with SGA (n = 5) and (2) controls (n = 10). 
Women were matched for gestational age at blood draw (Table 5). 
Preeclampsia was defined according to the criteria set by the 
American College of Obstetricians and Gynecologists (1) and 
was subdivided into preterm (<37 weeks) or term (≥37 weeks) 
groups. Severe preeclampsia was defined according to Sibai et al. 
(2). SGA was defined as neonatal BW below the 10th percentile 
for gestational age. Healthy controls had no medical or obstetric 
complications and delivered a neonate with a BW appropriate for 
gestational age.
Peripheral blood samples were obtained by venipuncture in 
the first trimester. Plasma samples were separated by double cen-
trifugation for 10 min. Samples were stored in aliquots at −80oC.
Sample Preparations
All solvents were HPLC-grade from Sigma-Aldrich (St. Louis, 
MO, USA) and all chemicals, where not stated otherwise, were 
obtained from Sigma-Aldrich. Frozen plasma samples were 
thawed and denatured with denaturing buffer (Biognosys AG; 
Schlieren, Switzerland). Samples were alkylated using alkyla-
tion solution (Biognosys). Subsequently, samples were digested 
overnight with sequencing grade modified trypsin (Promega; 
Madison, WI, USA) at a protein:protease ratio of 50:1. C18 
cleanup for mass spectrometry was carried out according to the 
manufacturer’s instructions using C18 Micro Spin columns (Nest 
Group Inc.; Southborough, MA, USA). Peptides were dried down 
to complete dryness using a SpeedVac system. Dried peptides 
were redissolved with LC solvent A (1% acetonitrile in water 
with 0.1% formic acid). Final peptide concentrations were deter-
mined for all samples by 280 nm measurement (SpectrostarNANO, 
BMG Labtech, Offenburg, Germany). Samples were spiked with 
PlasmaDive™ (Biognosys) reference peptides mix at known 
concentrations.
LC–MRM Measurements and Data Analysis
Peptides (1  µg per sample, corresponding to injection of 
0.0259 µl of initial plasma sample) were injected to a self-packed 
C18column [75  µm inner diameter and 10  cm column length, 
New Objective (Woburn, MA, USA); column material was Magic 
AQ, 3 µm particle size, and 200Å pore size from Michrom] on a 
ThermoScientific EASY-nLC1000 nano-liquid chromatography 
system. LC–MRM assays were measured on a ThermoScientific 
TSQ Vantage triple quadrupole mass spectrometer equipped 
with a standard nano-electrospray source. The LC gradient for 
LC–MRM was 6–40% solvent B (85% acetonitrile in water with 
0.1% formic acid) for 30 min followed by 40–94% solvent B for 
2  min and 94% solvent B for 8  min (total gradient length was 
40  min). A subset of Biognosys’ PlasmaDive™ MRM Panel of 
10 peptides representing 10 proteins (Data S9 in Supplementary 
Material) was used for the measurements of 10 altered proteins 
involved in immune responses. For the quantification of the pep-
tides across samples, the TSQ Vantage was operated in scheduled 
MRM mode with an acquisition window length of 5 min. The LC 
eluent was electrosprayed at 1.9 kV and Q1/Q3 were operated at 
unit resolution (0.7 Da). Signal processing and data analysis were 
carried out using SpectroDive™ 8.0—Biognosys’ software for 
multiplexed MRM/PRM data analysis based on mProphet (341). 
A q-value filter of 1% was applied.
Because of the small sample size of this pilot study, statistical 
simulations were carried out to predict power and significance in 
the extended validation study by multiple permutation testing. 
The probability of significant differences between the two groups 
was estimated by a paired t-test and the Mann–Whitney test. For 
both, p < 0.05 was taken as criteria to count successful simula-
tions. The number of successful simulations was calculated for 
different sample sizes (n = 10 or 100) and repeats of simulations 
(n = 10, 100, or 1,000). The simulated significance level at p < 0.05 
was accepted if the number of successful simulations was >25% 
(Figure 6; Data S9 in Supplementary Material).
Publication Search
An extensive PubMed search was conducted for first trimester 
maternal blood protein measurements of the DE proteins found 
by 2D-DIGE. Altogether five scientific reports were identified that 
met the inclusion criteria (126, 143, 239–241). Figure 6 depicts 
biomarkers with the same direction differential abundance in 
preterm preeclampsia in published data as in 2D-DIGE assays.
Trophoblast study
In Vitro Modeling of Placental Disease Pathways
Database Search and Data Analysis
To build optimal in vitro cellular models of trophoblastic disease, 
an extensive PubMed search was first conducted for similar 
assays. Since no human trophoblastic stems cells were yet avail-
able that would enable a natural proliferative trophoblastic pool 
with differentiation potential into villous or extravillous lineages, 
choriocarcinoma-derived trophoblastic cell lines or immortal-
ized EVTs were mostly used for such purposes. Our search 
revealed BeWo cells (342) and HTR8/SVneo cells (253) as the 
increasingly most accepted cell model systems based on 1,500 
published articles.
Primary VT Differentiation
For in  vitro trophoblast experiments, placentas (n =  6) were 
collected prospectively at the Perinatology Research Branch 
(NICHD, NIH, DHHS) from normal pregnant women at 
term who delivered an AGA neonate with Cesarean section. 
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Cytotrophoblasts were isolated from these placentas by the modi-
fied method of Kliman et al. (343). Briefly, 100 g villous tissues 
were cut, rinsed in PBS, and sequentially digested with Trypsin 
(0.25%; Life Technologies, Grand Island, NY, USA) and DNAse 
I (60 U/ml; Sigma-Aldrich) for 90 min at 37oC. Dispersed cells 
were filtered through 100 µm Falcon nylon mesh cell strainers 
(BD Biosciences, San Jose, CA, USA), and then erythrocytes 
were lysed with 5  ml NH4Cl solution (Stemcell Technologies, 
Vancouver, BC, Canada). Washed and resuspended cells were 
layered over 20–50% Percoll gradients and centrifuged for 20 min 
at 1,200 × g. Trophoblast containing bands were collected and 
non-trophoblastic cells were excluded by negative selection 
using anti-CD9 (20  µg/ml) and anti-CD14 (20  µg/ml) mouse 
monoclonal antibodies (R&D Systems, Minneapolis, MN, USA), 
MACS anti-mouse IgG microbeads, and MS columns (Miltenyi 
Biotec, Auburn, CA, USA). Then, primary VTs were plated on 
a collagen-coated 12-well plate (BD Biosciences; 3 ×  106 cells/
well) in Iscove’s modified Dulbecco’s medium (IMDM; Life 
Technologies) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin (P/S). To test the effect of 
trophoblast differentiation on selected genes’ expression, primary 
trophoblasts were kept in IMDM containing 5% non-pregnant 
human serum (SeraCare, Milford, MA, USA) and 1% P/S. The 
medium was replenished every 24 h, and cells were harvested for 
total RNA every 24 h between days 1 and 7.
The Effect of Maternal Serum on Trophoblastic Gene 
Expression
Villous trophoblasts were isolated from normal term placentas 
and plated as described above. To test the effect of preeclampsia 
serum on VTs at two time points of differentiation, VTs were kept 
in IMDM containing 1% P/S and 10% first trimester maternal sera 
from control or preeclamptic women. Medium was replenished 
after 48 h, and cells were harvested for total RNA either 24 or 72 h 
after the start of the human serum treatment. All experiments 
were run in triplicate.
The Effect of Oxygen Levels, BCL6, and ARNT2 Overexpression 
on Trophoblastic Gene Expression
BeWo cells (American Type Culture Collection) were incubated 
in a T-25 flask or 6-well plate with Ham’s F12-K medium (Life 
Technologies) supplemented with 10% FBS and 1% P/S in a 
humidified incubator (5% CO2, 20% O2) at 37oC until reaching 
50–80% confluence. To test the effect of ARNT2 or BCL6 overex-
pression on gene expression, cells were transiently transfected with 
ARNT2, BCL6, or control (GFP) vectors. Briefly, 4 µg expression 
plasmid (OriGene Technologies, Inc., Rockville, MD, USA) and 
12 µl FuGENE HD transfection reagent (Promega) were mixed 
with 180 µl Ham’s F12-K medium (10% FBS, 1% P/S), incubated 
at RT for 15 min and added to cell cultures with 1.8 ml medium 
in each well of 6-well plate. Twenty-four hours after transfection, 
cells were split into three treatment groups and kept under either 
normoxic (20% O2), hypoxic (2% O2), or ischemic (1% and 20% O2 
alternating for 6 h) conditions in an Oxycycler C42 (BioSpherix, 
Lacona, NY, USA) for 48 h before cell harvest. This study setup 
followed the generally accepted view in reproductive sciences 
that ~2% O2 concentration represents physiologic hypoxia at the 
implantation site and that placental development occurs under 
physiologic hypoxia in the first trimester (242, 344).
Total RNA Isolation and qRT-PCR
Total RNA was isolated from primary VTs on days 0–7 of dif-
ferentiation and from BeWo cell cultures with TRIzol reagent 
(Life Technologies) and RNeasy kit (QIAGEN) according to 
the manufacturers’ recommendations. The 28S/18S ratios and 
the RNA integrity numbers were assessed using an Agilent 
Bioanalyzer 2100; RNA concentrations were measured with 
NanoDrop 1000. Total RNA (500  ng) was reverse transcribed 
with High Capacity cDNA Reverse Transcription Kit using ran-
dom hexamers (Applied Biosystems). TaqMan Assays (Applied 
Biosystems; Data S17 in Supplementary Material) were used 
for high-throughput gene expression profiling on the Biomark 
qRT-PCR system (Fluidigm) according to the manufacturers’ 
instructions.
Data Analysis
qRT-PCR. Data were analyzed using the ΔΔCt method. Data 
were first normalized to the reference gene (RPLP0), and log2 
mRNA relative concentrations were obtained for each sample as 
−ΔCt(gene) = Ct(RPLPO) − Ct(gene).
Primary Trophoblast Differentiation. The overall changes in 
gene expression during the 7  days of differentiation were ana-
lyzed by comparing the mean expressions on a given day versus 
Day 0. The highest fold change for a given gene was defined as the 
maximum of the daily expression differences during the 7-day 
time-period. Significant differences were defined by a paired 
t-test (p < 0.05) (Figure 7).
Serum Treatment of Primary Trophoblast. Gene expression data 
were analyzed using the Student’s t-test to compare the effect of 
preeclampsia serum with the effect of control serum on gene 
expression at Days 1 and 3 of trophoblast differentiation. P-values 
of <0.05 were considered significant (Figure 6).
BeWo Cell Transfections. Gene expression data were analyzed 
to compare the effect of ARNT2 or BCL6 overexpression with 
the effect of control vector overexpression on gene expression in 
normoxic conditions using a one-way ANOVA model. The same 
model was used to assess the differential effect of ARNT2, BCL6, 
or GFP overexpression on gene expression in hypoxic or ischemic 
conditions vs. normoxia. P-values of <0.05 were considered sig-
nificant (Figure 8).
A permutation test was used to measure the statistical sig-
nificance of the matching between differential gene expression 
patterns in in vitro and in vivo conditions. Genes were discretized 
into three states, i.e. up-regulated (UP), down-regulated (DN), 
or unchanged (NS). For each gene in the two conditions, a score 
of 1 was assigned for a perfect match of UP/UP or DN/DN, 0 
for a neutral match of NS/NS, −1 for a perfect mismatch of UP/
DN or DN/UP, and −0.5 for all other patterns. The matching 
score for any pair of conditions was computed as the sum of all 
scores for each individual gene. The significance of the scores was 
assessed via a permutation on the class labels. Permutations were 
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exhaustive when feasible, otherwise limited to a random sample 
of 5,000 (Data S11 in Supplementary Material).
Evaluation of Placental/Trophoblastic Expression 
and Function of ZNF554
Tissue qRT-PCR Array Expression Profiling
TaqMan assays for ZNF554 and RPLP0 (Data S17 in Supplementary 
Material) were run in triplicate for expression profiling of the 
Human Major Tissue qPCR Array (OriGene Technologies) that 
contains cDNAs from 48 different pooled tissues.
mRNA In Situ Hybridization
In situ hybridization on third trimester FFPE placental tissues 
(n = 6) retrieved from the Bank of Biological Specimens of the 
Perinatology Research Branch was carried out using the RNAscope 
2.0 FFPE Assay–Brown (Advanced Cell Diagnostics, Hayward, 
CA, USA) on a HybEZ Hybridization System (Figure 9). Briefly, 
tissue sections were incubated with ZNF554 target probe (Cat.No.: 
423831, Advanced Cell Diagnostics) for 2 h at 40°C. After rinsing 
with 1× Wash Buffer, slides underwent a six-step amplification 
procedure at 40°C and were washed with 1× Wash Buffer between 
amplification steps. Chromogenic detection was performed using 
a 1:1 mixture of Brown-A and Brown-B solutions. Slides were 
counterstained with hematoxylin, dehydrated in graded ethanol, 
and mounted in xylene.
Immunohistochemistry
Third trimester placentas were retrieved from the Bank of 
Biological Specimens of the Perinatology Research Branch. 
First trimester placentas were collected from healthy Caucasian 
women undergoing termination of pregnancy and processed at 
the Maternity Clinic and Semmelweis University in Budapest, 
Hungary as described above. Five µm sections of first and third 
trimester FFPE placental tissues (n = 15) were placed on silanized 
slides and stained using anti-ZNF554 or anti-cytokeratin-7 
antibodies as well as reagents listed in Data S18 (Supplementary 
Material) either on Ventana Discovery (Ventana Medical Systems, 
Inc, Tucson, AZ, USA) or Leica BOND-MAX (Leica Microsystems, 
Wetzlar, Germany) autostainers (Figures 9 and 10).
Primary VT Differentiation
The experimental procedures were embedded in the study on VT 
differentiation as described above (Figure 9).
BeWo Cell Cultures
BeWo cells were incubated in a T-25 flask or 6-well plate with 
Ham’s F12-K medium (Life Technologies) supplemented with 
10% FBS and 1% P/S in a humidified incubator (5% CO2, 20% 
O2) at 37oC until reaching 50–80% confluence.
To test the effect of ZNF554 knockdown on gene expression, 
cells were treated either with 100 nM ZNF554 siRNA (Ambion-
Life Technologies, Foster City, CA, USA) or 100 nM scrambled 
(control) siRNA (Ambion) using X-tremeGENE siRNA transfec-
tion reagent (Roche, Mississauga, ON, Canada), and incubated at 
37oC in 2 ml serum-free Opti-MEM (Gibco-Life Technologies) 
medium. After 6 h, the medium was replaced with 2 ml Ham’s 
F12-K medium supplemented with 10% FBS. After 48  h, cells 
were collected for RNA isolation, microarray, and qRT-PCR as 
well as confocal microscopy (Figure 9).
To test the effect of DNA methylation on gene expression, 
BeWo cells were treated with 5 or 10 µM 5-azacitidine (Sigma-
Aldrich), and control cells with DMSO. This experiment was 
also performed when both 5-azacitidine-treated and control cells 
received 25 µM forskolin (Sigma-Aldrich) to induce syncytializa-
tion. After 24 h incubation, cells were harvested for RNA isolation 
and qRT-PCR. The experiment was performed in six replicates 
(Figure 11; Figure S8 in Supplementary Material).
HTR8/SVneo Cell Cultures
HTR8/SVneo EVT  cells (kindly provided by Dr. Charles H. 
Graham, Queen’s University, Kingston, Ontario, Canada) were 
incubated in a 6-well plate with RPMI-1640 medium (Gibco-
Life Technologies) supplemented with 10% FBS and 1% P/S in 
a humidified incubator (5% CO2, 20% O2) at 37oC until reaching 
50% confluence.
To test the effect of ZNF554 knockdown on gene expression 
and functions, cells were treated either with 100  nM ZNF554 
siRNA or 100  nM scrambled (control) siRNA as described 
for BeWo cells. After 6 h, the medium was replaced with 2 ml 
RPMI-1640 medium (Gibco-Life Technologies) supplemented 
with 10% FBS. On the following day, cells were kept in various O2 
concentrations (2, 8, or 20%) in an Oxycycler C42. Cells were col-
lected for functional assays after 24 h, while cells were collected 
for RNA isolation, microarray, qRT-PCR, or confocal microscopy 
and their supernatants for ELISA after 48 h. Cell cultures were 
used for cell proliferation assays after 0, 24, and 48 h.
Total RNA Isolation, Microarray, and qRT-PCR
Total RNA was isolated from BeWo and HTR8/SVneo cell 
cultures with TRIzol reagent (Life Technologies) and RNeasy kit 
(QIAGEN, Valencia, CA, USA) according to the manufacturers’ 
recommendations. The 28S/18S ratios and the RNA integrity 
numbers were assessed using an Agilent Bioanalyzer 2100; RNA 
concentrations were measured with NanoDrop 1000. DNase-
treated RNA from BeWo and HTR8/SVneo cells (500  ng) was 
amplified and biotin-labeled with the Illumina TotalPrep RNA 
Amplification Kit (Ambion-Life Technologies). Labeled cRNAs 
were hybridized to a HumanHT-12v4 Expression BeadChip 
(Illumina, Inc., San Diego, CA). BeadChips were imaged using a 
BeadArray Reader (Illumina, Inc.), and raw data were obtained 
with BeadStudio Software V.3.4.0 (Illumina, Inc.). Total RNA 
(500 ng) was also reverse transcribed with High Capacity cDNA 
Reverse Transcription Kit using random hexamers (Applied 
Biosystems, Foster City, CA, USA). TaqMan Assays (Applied 
Biosystems; Data S17 in Supplementary Material) were used for 
high-throughput gene expression profiling on the Biomark qRT-
PCR system (Fluidigm, San Francisco, CA, USA) according to the 
manufacturers’ instructions.
Confocal Microscopy
ZNF554 knock-down and control BeWo and HTR8/SVneo cells 
cultured in 6-well plate were detached with 0.05% Trypsin-EDTA 
(Life Technologies), washed, and resuspended in PBS, and then 
4 ×  104 cells were cytospined to Superfrost Plus slides (Fisher 
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Scientific). Then, cells were fixed with 4% paraformaldehyde 
(Electron Microscopy Sciences, Hatfield, PA, USA), blocked 
with Protein Block (Dako North America, Inc., Carpinteria, CA, 
USA), and immunostained with anti-ZNF554 mouse polyclonal 
antibody (1:100 dilution, overnight; Abnova, Taipei City, Taiwan) 
and an AlexaFluor-488 goat anti-mouse antibody (1:1,000 dilu-
tion; Life Technologies). Cells were mounted with ProLong Gold 
antifade reagent with 4’,6-diamidino-2-phenylindole (DAPI; Life 
Technologies), followed by confocal microscopy using a Leica 
TCS SP5 MP spectral confocal system (Leica Microsystems) 
(Figures 9 and 10).
Enzyme-Linked Immunosorbent Assays
Concentrations of human plasminogen activator inhibitor-1 
(PAI-1) and TIMP-3 in HTR8/SVneo cell culture supernatants 
were measured with sensitive and specific immunoassays (Human 
PAI-1 ELISA Kit, Invitrogen; TIMP-3 Human ELISA Kit, Abcam 
Inc., Cambridge, MA, USA) according to the manufacturers’ 
instructions. Standard curves were generated, and sample assay 
values were extrapolated. The sensitivities of the assays were 
<30 pg/mL (PAI-1) and <2 pg/ml (TIMP-3) (Figure 10).
Cell Proliferation Assays
Cell cultures of control and ZNF554 siRNA treated HTR8/
SVneo cells were assayed using the CellTiter 96 Aqueous Non-
radioactive Cell Proliferation Assay (Promega) according to 
the manufacturer’s instructions (Figure S11 in Supplementary 
Material).
Migration Assay
The migratory capacity of HTR8/SVneo cells was examined with 
8μm-pore transwell inserts (Corning, NY, USA) inserted in a 
12-well plate described previously (345). After transfection with 
ZNF554 or scrambled siRNAs for 24 h, 5 × 105 HTR8/SVneo cells 
were plated in the upper chambers in a serum-free RPMI-1640 
medium, whereas the lower chambers contained an RPMI-1640 
medium supplemented with 10% FBS. After incubation for 36 h 
in 2, 8, or 20% O2 concentrations, cells on the upper side of the 
membranes were removed by cotton swab, and the inserts were 
fixed in methanol for 10 min at RT and washed once with PBS. 
Then, the membranes were cut out and mounted on Superfrost 
Plus slides (Fisher Scientific) with ProLong Gold antifade reagent 
with DAPI. Comprehensive images of each membrane were taken 
using a Leica TCS SP5 MP spectral confocal system. The number 
of invaded cells was quantified using Image-Pro Premier v9.0.2 
(Media Cybernetics, Inc., Rockville, MD, USA). The experiment 
was performed in six replicates (Figure 10).
Matrigel Invasion Assay
The invasiveness of HTR8/SVneo cells was examined with a 
Matrigel invasion assay using 8  μm-pore cell culture inserts 
(BD Biosciences) pre-coated with Matrigel (125  ng/ml; BD 
Biosciences) and inserted in a 24-well plate described previously 
(345). After transfection with ZNF554 or scrambled siRNAs for 
24 h, 2 × 105 cells were plated in the upper chambers in a serum-
free RPMI-1640 medium, whereas an RPMI-1640 medium sup-
plemented with 10% FBS was added to the lower chambers. After 
incubation for 48 h in 2, 8, or 20% O2 concentrations, cells on the 
Matrigel side of the membranes were removed by cotton swab, 
and the membranes were processed as in the migration assay. 
Comprehensive images taken using the Leica TC5 SP5 spectral 
confocal system were quantified using Image-Pro Plus 6.2 (Media 
Cybernetics, Inc.). The experiment was performed in triplicate 
(Figure 10).
Data Analysis
Tissue qRT-PCR Array. The expression of ZNF554 relative to 
RPLP0 in the placenta was compared to 47 other human tissues 
using the Student’s t-test. P-values of <0.05 were considered sig-
nificant (Figure 9).
The Student’s t-test was used to evaluate ZNF554 knock-down 
efficiency and the effect of ZNF554 knock-down on gene expres-
sion in BeWo and HTR8/SVneo cells (Figures 9 and 10).
BeWo and HTR8/SVneo Cell Microarray. Data were analyzed 
using the Bioconductor packages in R (346) following the MIAME 
guidelines and methodologies described previously (318). Raw 
microarray gene expression data were normalized by a quantile 
normalization approach. A moderated t-test was used to select 
DE genes using a cutoff of >1.5 fold-change and q < 0.1. GO anal-
ysis and pathway analysis using the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway database were also performed.
HTR8/SVneo Cell qRT-PCR, Immunoassay, Cell Proliferation, 
Migration, and Invasion. qRT-PCR data were analyzed using the 
ΔΔCt method relative to RPLP0 expression. The Student’s t-test 
was used to evaluate ZNF554 knock-down efficiency in HTR8/
SVneo cells and the effect of ZNF554 knock-down on gene expres-
sion and cell proliferation. A linear model was built to quantify the 
effects of ZNF554 knock-down and various O2 concentrations on 
the gene expression and protein secretion of HTR8/SVneo cells as 
well as on their migratory and invasive capacity. O2 concentration 
was treated as a continuous variable, and the interaction between 
ZNF554 knock-down and O2 concentrations was retained in the 
model when the coefficient was significant. P-values of <0.05 
were considered significant (Figure 10).
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FigUre s1 | Hub transcription regulatory genes in the M1 and M2 modules and 
their interaction network. (a) Co-expression matrix of transcription regulatory 
genes and predominantly placenta-expressed genes in the M1 and M2 modules. 
Within the M1 (green) module, ESRRG, POU5F1, and ZNF554 transcription 
regulatory genes correlated most strongly with predominantly placenta-
expressed genes. ESRRG and ZNF554 had the most correlation with CSH1 and 
HSD11B2, genes strongly implicated in fetal growth. Within the M2 (red) module, 
BCL6, BHLHE40, and ARNT2 transcription regulatory genes were correlated 
most strongly with predominantly placenta-expressed genes. BCL6 and ARNT2 
had the most correlation with FLT1. Heatmap represents Pearson coefficients. 
(B,c) The networks of biological processes enriched among genes dysregulated 
in preeclampsia and co-expressed with hub factors in M1 (ZNF554) and M2 
(BCL6) modules were visualized with the BINGO module of Cytoscape. Sizes of 
the circles relate to the number of genes involved in the biological processes and 
colors refer to p-values. The groups of most enriched biological processes were 
manually circled and labeled. The color code depicts p-values.
FigUre s2 | Clinical characteristics in the transcriptomic validation study 
groups. Blood pressure, birth weight, and gestational age data from the 100 
pregnant women included in the validation study show that preeclampsia 
phenotypes are heterogeneous, underlining the complex pathways of disease in 
preeclampsia.
FigUre s3 | Placental gene expression changes in various phenotypes of 
preeclampsia detected by qRT-PCR. Data represent gene expressions relative 
to RPLP0 measured across 100 placentas. In each bar plot (mean ± SE), the 
left and right panels show significant differences (“*”) in preterm and term 
preeclampsia associated with or without SGA samples compared to 
gestational age-matched controls, respectively. Changes in preterm 
preeclampsia samples significantly different to changes in term preeclampsia 
samples are indicated by “+”.
FigUre s4 | The correlation between placental gene expression and maternal 
plasma protein concentration. Placental LEP and CSH1 gene expression was 
either measured with microarrays in the third trimester or with qRT-PCR in the 
first trimester. Maternal plasma leptin and serum human placental lactogen 
protein concentrations were measured with ELISA. Third trimester placental 
microarray data were correlated with ELISA data from maternal blood samples 
collected at the time of delivery from the same patients. qRT-PCR data from 
placentas taken from first trimester terminations were correlated with ELISA data 
from blood samples collected at the time of the procedure from the same 
patients. Correlations were investigated with the Pearson method and visualized 
on scatter plots. The two investigated genes’ expression and their protein 
products’ concentrations correlated both in the first and third trimesters.
FigUre s5 | The timing of gene module dysregulation in preterm preeclampsia. 
(a) Human microarray data on 79 human tissues and cells downloaded from the 
BioGPS database was used for the generation of placenta enrichment scores 
(placental expression/mean expression in 78 other tissues and cells). Five genes 
with scores between 1.4 and 1,490 were selected based on literature search due 
to the extensive investigations of their gene products in maternal blood in 
preeclampsia. Colors depict gene module involvement. (B–F) The 80,170 
measurements for five gene products published in 61 scientific reports (35, 61, 
82, 88, 126, 178–233) were used for the virtual liquid biopsy of the placenta in 
preterm preeclampsia. Biomarker levels in preterm preeclampsia were expressed 
as the percentage of control levels (dotted lines) throughout pregnancy. 
Percentage values were represented in the scatter plots by different colors 
reflecting gene module classification. Based on qRT-PCR data, sEng belongs to 
M2 (red) module. The number of measurements, the Pearson correlation values 
for biomarker levels, and gestational age as well as corresponding p-values are 
depicted for each biomarker.
FigUre s6 | Maternal blood proteomic changes in term preeclampsia and their 
effect on differentially expressed (DE) genes in the placenta. (a) The 14 DE 
maternal serum proteins in term preeclampsia belong to six functional groups. 
(B) These 14 proteins have connections with 116 DE placental genes, among 
which 46 belong to the M2 (red) module. Angiotensinogen has more connections 
than other proteins (OR = 2.5, p = 1.6 × 10−8) and the most with M2 (red) 
module genes (n = 35). Seventy seven of 86 connections of angiotensinogen 
have a directional effect toward the gene.
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FigUre s7 | Summary of functional experiments on module M2. Epigenetic 
changes to the trophoblast and abnormal trophoblast differentiation lead to a 
general down-regulation of gene expression and the up-regulation of hub factors 
in module M2 (e.g. BCL6). After placental circulation has been established and 
placental ischemic stress occurs, the up-regulation of BCL6 sensitizes the 
trophoblast to ischemia by inducing ARNT2 up-regulation and downstream 
increase of expression of FLT1, ENG, LEP, leading to the placental release of 
pro-inflammatory and anti-angiogenic gene products. This pathway is only 
observed in preterm preeclampsia, suggesting that the dysregulation of this 
placental pathway promotes the early development of preeclampsia. The 
alterations in maternal blood proteome can induce trophoblastic functional 
changes leading to the up-regulation of module M2 genes, the overproduction of 
sFlt-1 and an anti-angiogenic state through a trajectory that does not necessarily 
affect fetal growth.
FigUre s8 | DNA methylation regulates BCL6 expression in the trophoblast. (a) 
Decreased BCL6 expression was observed in BeWo cells upon treatment with 
5-azacitidine (5-AZA) irrespective of Forskolin (FRSK) co-treatment. (B) Upper 
three lanes: whole genome bisulfite sequencing data of BCL6 first intron from the 
Human Reference Epigenome Mapping Project. H1 ESC; H1 embryonic stem 
cell; HBDT, H1 BMP4-derived trophoblast; and HDNP, H1-derived neuronal 
progenitor. Lower three lanes: bisulfite sequencing data in this study. 
Abbreviations: CB, cord blood cell; CT, cytotrophoblast; ST, syncytiotrophoblast. 
Red box: differentially methylated region; red arrow: CpG Chr3:187458163.
FigUre s9 | DNA methylation levels at individual CpGs in BCL6 in the 
trophoblast and umbilical cord blood cells. DNA methylation levels (0–100%) at 
individual CpGs in BCL6 in umbilical cord blood cells (CB), cytotrophoblasts (CT), 
and differentiated syncytiotrophoblasts (ST) are depicted in the bar plots that 
represent means and SEs. Umbilical cord blood cells and cytotrophoblasts were 
obtained from the same fetuses. The genomic coordinates of the CpGs, the 
group differences (CB vs. CT; CT vs. ST) in mean DNA methylation levels and the 
p-values are shown above the bar plots. The number of samples analyzed with 
methylation reads above the threshold are shown below the bar plots (only 
comparisons with a group sample size of minimum two were considered). 
Differential methylation was claimed to be mild, moderate, or strong when the 
p-value was <0.05 and the difference in methylation level was ≥0.125, ≥0.25, or 
≥0.5, respectively.
FigUre s10 | DNA methylation levels at individual CpGs in BCL6 in the 
trophoblast in controls and in cases of preeclampsia. DNA methylation levels 
(0–100%) at individual CpGs in BCL6 in laser captured trophoblasts are depicted 
in the bar plots that represent means and SEs. The genomic coordinates of the 
CpGs, the group differences (compared preterm or term controls) in DNA 
methylation levels and the p-values are shown above the bar plots. The number 
of samples analyzed with methylation reads above the threshold are shown 
below the bar plots (only comparisons with a group sample size of minimum four 
were considered). Differential methylation was claimed to be mild, moderate, or 
strong when the p-value was <0.05 and the difference in methylation level was 
≥0.125, ≥0.25, or ≥0.5, respectively. Preterm (left) and term (right) groups of 
patients were analyzed separately. Abbreviations: PE, preeclampsia; PE + SGA, 
preeclampsia associated with small-for-gestational age.
FigUre s11 | The effect of ZNF554 knock-down on cell proliferation in HTR8/
SVneo extravillous trophoblastic cells. (a) Cell proliferation assays showed that 
ZNF554 knock-down slightly but significantly decreased (−14%, p = 0.02) cell 
proliferation rate in HTR8/SVneo extravillous trophoblastic cells after 48 h. Y-axis 
depicts viable cell number, X-axis shows incubation time. (B) The differential 
expression of CDKN1A (cyclin-dependent kinase inhibitor 1A) and STK40 (serine/
threonine kinase 40), genes involved in the regulation of cell cycle, upon ZNF554 
knock-down was confirmed by qRT-PCR.
FigUre s12 | DNA methylation levels at individual CpGs in ZNF554 in the 
trophoblast and umbilical cord blood cells. DNA methylation levels (0–100%) at 
individual CpGs in ZNF554 in umbilical cord blood cells (CB), cytotrophoblasts 
(CT), and differentiated syncytiotrophoblasts (ST) are depicted in the bar plots 
that represent means and SEs. Umbilical cord blood cells and CT were obtained 
from the same fetuses. The genomic coordinates of the CpGs, the group 
differences (CB vs. CT; CT vs. ST) in mean methylation levels and the p-values 
are shown above the bar plots. The number of samples analyzed with 
methylation reads above the threshold are shown below the bar plots (only 
comparisons with a group sample size of minimum two were considered). 
Differential methylation was claimed to be mild, moderate, or strong when the 
p-value was <0.05 and the difference in methylation level was ≥0.125, ≥0.25, or 
≥0.5, respectively.
FigUre s13 | DNA methylation levels at individual CpGs in ZNF554 in the 
trophoblast in controls and in cases of preeclampsia. DNA methylation levels 
(0–100%) at individual CpGs in ZNF554 in laser captured trophoblasts are 
depicted in the bar plots that represent means and SEs. The genomic 
coordinates of the CpGs, the group differences (compared preterm or term 
controls) in methylation levels, and the p-values are shown above the bar plots. 
The number of samples analyzed with methylation reads above the threshold are 
shown below the bar plots (only comparisons with a group sample size of 
minimum four were considered). Differential methylation was claimed to be mild, 
moderate, or strong when the p-value was <0.05 and the difference in 
methylation level was ≥0.125, ≥0.25, or ≥0.5, respectively. Preterm (left) and 
term (right) groups of patients were analyzed separately. Abbreviations: PE, 
preeclampsia; PE + SGA, preeclampsia associated with SGA.
DaTa s1 | Genes differentially expressed in the placenta in preterm 
preeclampsia.
DaTa s2 | Predominantly placenta-expressed genes.
DaTa s3 | The enrichment of differentially expressed genes on chromosomes.
DaTa s4 | The enrichment of differentially expressed transcription regulatory 
genes on chromosomes.
DaTa s5 | The enrichment of predominantly placenta-expressed genes on 
chromosomes.
DaTa s6 | Genes associated with blood pressure.
DaTa s7 | The association of gene expression with placental pathology.
DaTa s8 | Maternal blood proteomic changes in preeclampsia—two-
dimensional differential in-gel electrophoresis.
DaTa s9 | Maternal blood proteomic changes in preeclampsia—multiple 
reaction monitoring.
DaTa s10 | Placental pathways enriched among the differentially expressed genes 
connected to angiotensinogen.
DaTa s11 | Permutation test of functional experiments.
DaTa s12 | Enrichment of transposable elements in genes within the M1 and 
M2 gene modules.
DaTa s13 | Genes differentially expressed in ZNF554-silenced BeWo cells.
DaTa s14 | Enrichment analysis of ZNF554-silenced BeWo cells.
DaTa s15 | Genes differentially expressed in ZNF554-silenced HTR8/ 
SVneo cells.
DaTa s16 | Enrichment analysis of ZNF554-silenced HTR8/SVneo cells.
DaTa s17 | TaqMan assays.
DaTa s18 | Immunostaining conditions and antibodies.
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